nvcr-10q_20160630.htm

0001564590-16-021602.txt : 20160728 0001564590-16-021602.hdr.sgml : 20160728 20160728065358 ACCESSION NUMBER: 0001564590-16-021602 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160728 DATE AS OF CHANGE: 20160728 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Novocure Ltd CENTRAL INDEX KEY: 0001645113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37565 FILM NUMBER: 161788280 BUSINESS ADDRESS: STREET 1: LE MASURIER HOUSE, LA RUE LE MASURIER CITY: ST. HELIER STATE: Y9 ZIP: JE2 4YE BUSINESS PHONE: 44 (0)15 3475 6700 MAIL ADDRESS: STREET 1: LE MASURIER HOUSE, LA RUE LE MASURIER CITY: ST. HELIER STATE: Y9 ZIP: JE2 4YE 10-Q 1 nvcr-10q_20160630.htm FORM 10-Q nvcr-10q_20160630.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-37565

NovoCure Limited

(Exact Name of Registrant as Specified in Its Charter)

Jersey (Channel Islands)		98-1057807
(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation or Organization)		Identification No.)

Le Masurier House

La Rue Le Masurier

St. Helier, Jersey JE2 4YE

(Address of principal executive offices)

+44 (0) 15 3475 6700

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name, Former Address and Former Fiscal Year, If Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No o.

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	o			Accelerated filer	o
Non-accelerated filer	x		(Do not check if a smaller reporting company)	Smaller reporting company	o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x.

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date.

Class		Outstanding as of July 26, 2016
Ordinary shares, no par value		85,774,774 Shares

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

In addition to historical facts or statements of current condition, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements contained in this report are based on our current plans, expectations, hopes, beliefs, intentions or strategies concerning future developments and their impact on us. Forward-looking statements contained in this report constitute our expectations or forecasts of future events as of the date this report was filed with the Securities and Exchange Commission and are not statements of historical fact. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Such statements may include words such as “anticipate,” “will,” “estimate,” “expect,” “project,” “intend,” “should,” “plan,” “believe,” “hope,” and other words and terms of similar meaning in connection with any discussion of, among other things, future operating or financial performance, strategic initiatives and business strategies, regulatory or competitive environments, our intellectual property and delivery system research and development. In particular, these forward-looking statements include, among others, statements about:

our research and development, clinical trial and commercialization activities and projected expenditures;

the further commercialization of Optune®, our first Tumor Treating Fields (“TTFields”) delivery system, and our other TTFields delivery system candidates;

our business strategies and the expansion of our sales and marketing efforts in the United States and in other countries;

the market acceptance of Optune and our other TTFields delivery systems by patients, physicians, third-party payers and others in the healthcare and scientific community;

our plans to pursue the use of TTFields for the treatment of other solid tumor cancers;

our estimates regarding revenues, expenses, capital requirements and needs for additional financing;

our ability to obtain regulatory approvals for additional indications and any future TTFields delivery systems;

our ability to acquire the supplies needed to manufacture our TTFields delivery systems from third-party suppliers;

our ability to manufacture adequate supply;

our ability to secure adequate coverage from third-party payers to reimburse us for Optune or future TTFields delivery systems;

our ability to maintain and develop our intellectual property position;

our cash needs; and

our prospects, financial condition and results of operations.

These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respect s from those projected in these forward-looking statements. Factors which may cause such differences to occur include those risks and uncertainties set forth under Part I, Item 1A., “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as well as other risks and uncertainties set forth from time to time in the reports we file with the U.S. Securities and Exchange Commission. We do not intend to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

TRADEMARKS

This Quarterly Report on Form 10-Q includes trademarks of NovoCure Limited and other persons. All trademarks or trade names referred to herein are the property of their respective owners.

NovoCure Limited

Quarterly Report on Form 10-Q

TABLE OF CONTENTS

		Page
Cautionary Note Regarding Forward Looking Statements		ii

PART I—FINANCIAL INFORMATION

Item 1.	Financial Statements	2
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
Item 4.	Controls and Procedures	19

PART II—OTHER INFORMATION


Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 5.	Other Information	20
Item 6.	Exhibits	21

	Signatures	22

- 1 -

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

NOVOCURE LIMITED AND SUBSIDIARIES

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

	June 30,		December 31,
	2016		2015
	Unaudited		Audited
ASSETS

CURRENT ASSETS:
Cash and cash equivalents	$	80,871	$	119,423
Short-term investments		119,979		150,001
Restricted cash		99		87
Receivables and prepaid expenses		12,534		10,799
Inventories		21,215		13,594
Total current assets		234,698		293,904

LONG-TERM ASSETS:
Property and equipment, net		8,813		6,552
Field equipment, net		5,850		6,029
Severance pay fund		82		79
Other long-term assets		1,076		772
Total long-term assets		15,821		13,432

TOTAL ASSETS	$	250,519	$	307,336

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

- 2 -

NOVOCURE LIMITED AND SUBSIDIARIES

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except share data)

	June 30,			December 31,
	2016			2015
	Unaudited			Audited
LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:
Trade payables	$	22,007		$	16,755
Other payables and accrued expenses		12,611			11,872
Total current liabilities		34,618			28,627

LONG-TERM LIABILITIES:
Long-term loan, net of discount and issuance costs		23,292			23,097
Employee benefit liabilities		2,592			2,057
Other long-term liabilities		3,371			2,735
Total long-term liabilities		29,255			27,889

TOTAL LIABILITIES		63,873			56,516

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY:
Share capital -
Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 85,774,774 shares and 83,778,581 shares at June 30, 2016 and December 31, 2015, respectively		-			-
Additional paid-in capital		652,460			640,406
Accumulated other comprehensive loss		(1,684	)		(1,505	)
Accumulated deficit		(464,130	)		(388,081	)
Total shareholders' equity		186,646			250,820

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	250,519		$	307,336

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

- 3 -

NOVOCURE LIMITED AND SUBSIDIARIES

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS

U.S. dollars in thousands (except share and per share data)

	Three months ended June 30,						Six months ended June 30,						Year ended December 31,
	2016			2015			2016			2015			2015
	Unaudited						Unaudited						Audited
Net revenues	$	17,919		$	6,543		$	30,972		$	11,751		$	33,087
Cost of revenues		9,797			4,750			17,779			8,647			20,610
Impairment of field equipment		6,412			-			6,412			-			-

Gross profit		1,710			1,793			6,781			3,104			12,477

Operating costs and expenses:
Research, development and clinical trials		11,318			12,765			22,763			22,692			43,748
Sales and marketing		14,598			8,866			27,906			15,221			38,861
General and administrative		13,031			7,368			25,287			14,343			33,864

Total operating costs and expenses		38,947			28,999			75,956			52,256			116,473

Operating loss		(37,237	)		(27,206	)		(69,175	)		(49,152	)		(103,996	)
Financial expenses, net		555			876			1,104			1,467			3,151

Loss before income tax expense		(37,792	)		(28,082	)		(70,279	)		(50,619	)		(107,147	)
Income tax expense		2,820			1,275			5,770			2,011			4,434

Net loss	$	(40,612	)	$	(29,357	)	$	(76,049	)	$	(52,630	)	$	(111,581	)

Basic and diluted net loss per ordinary share	$	(0.48	)	$	(2.36	)	$	(0.90	)	$	(4.12	)	$	(3.67	)

Weighted average number of ordinary shares used in computing basic and diluted net loss per share		85,274,683			12,427,442			84,843,028			12,783,881			30,401,603

CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME

U.S. dollars in thousands

	Three months ended June 30,						Six months ended June 30,						Year ended December 31,
	2016			2015			2016			2015			2015
	Unaudited						Unaudited						Audited
Net loss	$	(40,612	)	$	(29,357	)	$	(76,049	)	$	(52,630	)	$	(111,581	)
Other comprehensive loss, net of tax :
Change in foreign currency translation adjustments		56			-			56			-			-
Pension benefit plan		235			-			(235	)		-			(1,505	)
Total comprehensive loss	$	(40,321	)	$	(29,357	)	$	(76,228	)	$	(52,630	)	$	(113,086	)

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

- 4 -

NOVOCURE LIMITED AND SUBSIDIARIES

CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

U.S. dollars in thousands (except share data)

	Ordinary shares			Preferred shares			Additional paid-in		Accumulated other comprehensive			Accumulated			Total shareholders'
	Shares			Shares			capital		loss			deficit			equity
Balance as of January 1, 2015 (audited)		13,431,414			58,676,017		$	374,375	$	-		$	(276,500	)	$	97,875
Share-based compensation to employees		-			-			11,860		-			-			11,860
Exercise of options and warrants		731,665			-			2,038		-			-			2,038
Issuance of Series J preferred shares, net (a)		-			4,068,500			94,599		-			-			94,599
Issuance of shares and options in respect of settlement, net of fair value of shares provided as indemnification		(1,005,210	)		-			-		-			-			-
Issuance of ordinary shares upon IPO and exercise of over-allotment, net (b)		7,876,195			-			157,534		-			-			157,534
Conversion of preferred shares to ordinary shares		62,744,517			(62,744,517	)		-		-			-			-
Other comprehensive loss, net of tax benefit		-			-			-		(1,505	)		-			(1,505	)
Net loss		-			-			-		-			(111,581	)		(111,581	)
Balance as of December 31, 2015 (audited)		83,778,581			-			640,406		(1,505	)		(388,081	)		250,820
Share-based compensation to employees		-			-			11,093		-			-			11,093
Exercise of options and warrants		1,996,193			-			961		-			-			961
Other comprehensive loss, net of tax benefit		-			-			-		(179	)		-			(179	)
Net loss		-			-			-		-			(76,049	)		(76,049	)
Balance as of June 30, 2016 (unaudited)		85,774,774			-		$	652,460	$	(1,684	)	$	(464,130	)	$	186,646

(a) Net of issuance expenses of $319

(b) Net of issuance expenses (including underwriter fees) of $15,742

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

- 5 -

NOVOCURE LIMITED AND SUBSIDIARIES

CONDENSED INTERIM CONSOLIDATED CASH FLOWS

U.S. dollars in thousands

	Three months ended June 30,						Six months ended June 30,						Year ended December 31,
	2016			2015			2016			2015			2015
	Unaudited						Unaudited						Audited
Cash flows from operating activities:
Net loss	$	(40,612	)	$	(29,357	)	$	(76,049	)	$	(52,630	)	$	(111,581	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,407			588			2,510			1,112			3,153
Asset write-downs and impairment of field equipment		6,425			11			6,430			42			46
Accrued interest expense		(637	)		307			-			719			672
Share-based compensation to employees		5,637			2,632			11,093			4,444			11,860
Amortization of discount (premium)		(39	)		88			(56	)		143			329
Increase in receivables and prepaid expenses		(1,672	)		(2,079	)		(2,208	)		(3,026	)		(5,088	)
Increase in inventories		(4,769	)		(1,415	)		(7,621	)		(5,147	)		(10,148	)
Increase in other long-term assets		(111	)		(161	)		(278	)		(171	)		(381	)
Increase in trade payables		2,321			3,757			4,144			3,085			6,961
Increase in other payables and accrued expenses		2,399			3,237			756			518			3,579
Increase in employee benefit liabilities, net		32			-			270			7			133
Increase (decrease) in other long-term liabilities		225			(799	)		638			(753	)		581
Net cash used in operating activities	$	(29,394	)	$	(23,191	)	$	(60,371	)	$	(51,657	)	$	(99,884	)

Cash flows from investing activities:
Purchase of property and equipment	$	(2,338	)	$	(1,808	)	$	(3,340	)	$	(2,417	)	$	(4,667	)
Purchase of field equipment		(4,274	)		(1,142	)		(6,100	)		(2,180	)		(5,604	)
Decrease (increase) in restricted cash		(13	)		40			(12	)		(33	)		(26	)
Proceeds from maturity of short-term investments		-			2,000			150,000			47,000			104,000
Purchase of short-term investments		-			(36,995	)		(119,728	)		(58,992	)		(208,998	)
Net cash provided by (used in) investing activities	$	(6,625	)	$	(37,905	)	$	20,820		$	(16,622	)	$	(115,295	)

Cash flows from financing activities:
Proceeds from issuance of shares, net	$	-		$	94,599		$	-		$	94,599		$	252,133
Proceeds from long-term loan, net		17			(920	)		17			22,886			22,886
Deferred IPO costs		-			(294	)		-			(294	)		-
Repayment of other long-term loan		(19	)		(15	)		(35	)		(31	)		(63	)
Purchase of shares in respect of settlement		-			-			-			(5	)		(5	)
Exercise of options and warrants		904			16			961			19			2,038
Net cash provided by financing activities	$	902		$	93,386		$	943		$	117,174		$	276,989

Effect of exchange rate changes on cash and cash equivalents	$	56		$	-		$	56		$	-		$	-

Increase (decrease) in cash and cash equivalents		(35,061	)		32,290			(38,552	)		48,895			61,810
Cash and cash equivalents at the beginning of the period		115,932			74,218			119,423			57,613			57,613

Cash and cash equivalents at the end of the period	$	80,871		$	106,508		$	80,871		$	106,508		$	119,423

Supplemental cash flow activities:
Cash paid during the period for:
Income taxes	$	1,587		$	171		$	3,169		$	266		$	1,489
Interest	$	1,269		$	422		$	1,933		$	428		$	1,688

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements

- 6 -

NOVOCURE LIMITED AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share data)

NOTE 1: ORGANIZATION AND BASIS OF PRESENTATION

Organization. NovoCure Limited (including its consolidated subsidiaries, the “Company”) was incorporated in Jersey and is principally engaged in the development, manufacture and commercialization of TTFields for the treatment of solid tumors. Since inception, the Company has devoted substantially all of its efforts to developing and commercializing a family of products to deliver TTFields for a variety of solid tumor indications, raising capital and recruiting personnel. The Company has regulatory approvals and clearances in certain countries for Optune, its first TTFields delivery system, to treat glioblastoma (“GBM”). The Company commenced marketing Optune in the United States at the end of 2011, in certain countries in Europe in 2014 and in Japan in 2015.

Financial statement preparation. The accompanying condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries, and intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the “2015 10-K”) filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2016.

The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the 2015 10-K are applied consistently in these unaudited interim consolidated financial statements.

Recently Issued Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In April 2016, FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASU 2016-10 covers two specific topics: performance obligations and licensing. This amendment includes guidance on immaterial promised goods or services, shipping or handling activities, separately identifiable performance obligations, functional or symbolic intellectual property licenses, sales-based and usage-based royalties, license restrictions (time, use, geographical) and licensing renewals. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In May 2016, FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and

- 7 -

complexity of applying Topic 606 both at transition and on an ongoing basis. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

NOTE 2: SHORT-TERM INVESTMENTS

The Company invests in marketable U.S. Treasury Bills (“T-bills”) that are classified as held-to-maturity securities. The amortized cost and recorded basis of the T-bills are presented as short-term investments in the amount of $119,979 and $150,001 as of June 30, 2016 and December 31, 2015, respectively, and their estimated fair value as of June 30, 2016 and December 31, 2015 was $119,845 and $149,978, respectively.

NOTE 3: INVENTORIES

Inventories are stated at the lower of cost or market. The weighted average methodology is applied to determine cost. As of June 30, 2016 and December 31, 2015, the Company’s inventories were composed of:

	June 30,		December 31,
	2016		2015
	Unaudited		Audited
Raw materials	$	3,192	$	3,518
Work in progress		5,031		4,618
Finished products		12,992		5,458
Total	$	21,215	$	13,594

NOTE 4: COMMITMENTS AND CONTINGENT LIABILITIES

The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2023. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2019.

As of June 30, 2016 and December 31, 2015, the Company pledged bank deposits of $381 and $133, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained guarantees by the bank for the fulfillment of the Company’s lease commitments of $532 and $283, respectively.

NOTE 5: SHARE CAPITAL

For the six months ended June 30, 2016, warrants to purchase 220,316 ordinary shares with an exercise price of $3.59 were exercised, resulting in the issuance of 220,316 ordinary shares, and warrants to purchase 975,644and 888,219 ordinary shares with exercise prices of $18.09 and $3.59 per share, respectively, were cashlessly exercised, resulting in the issuance of 950,637 ordinary shares. For the six months ended June 30, 2016, options to purchase 825,240 ordinary shares were exercised, resulting in the issuance of 825,240 ordinary shares. For additional information on option exercises, please see Note 6.

NOTE 6: EQUITY INCENTIVE PLAN

In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the “2015 Plan”). The 2015 Plan replaced the 2013 Share Option Plan. Under the 2015 Plan, the Company can issue various types of equity compensation awards such as restricted shares, performance shares, restricted stock units, performance units, long-term cash award and other share-based awards.

The options granted under the 2015 Plan generally have a four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are cancelled or forfeited before expiration become available for future grant.

As of June 30, 2016, 12,898,636 ordinary shares were available for grant under the 2015 Plan.

- 8 -

A summary of the status of the Company’s option plans as of June 30, 2016 and changes during the period then ended is presented below:

	Six months ended June 30, 2016
	Unaudited
	Number of options			Weighted average exercise price
Outstanding at beginning of year		10,134,829		$	8.20
Granted		2,127,275			13.86
Exercised		(825,240	)		0.21
Forfeited and cancelled		(78,243	)		17.86

Outstanding as of June 30, 2016		11,358,621			9.77

Exercisable options		5,586,108			4.86

Vested and expected to vest		11,157,637		$	9.71

The fair value of share-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions:

	Six months ended June 30,			Year ended December 31,
	2016	2015		2015
	Unaudited			Audited
Expected term (years)	6.25		6.25	6.25
Expected volatility	59.80%-61.65%	62.5% - 65.8%		59.00%-65.80%
Risk-free interest rate	1.23%-1.88%	1.75% - 1.9%		1.74%-2.05%
Dividend yield	0%	0%		0%

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and six months ended June 30, 2016 and 2015 and the year ended December 31, 2015 was:

	Three months ended June 30,				Six months ended June 30,				Year ended December 31,
	2016		2015		2016		2015		2015
	Unaudited				Unaudited				Audited
Cost of revenues	$	170	$	6	$	311	$	19	$	174
Research, development and clinical trials		839		628		1,602		1,049		2,529
Sales and marketing		1,349		571		2,639		979		2,496
General and administrative		3,279		1,427		6,541		2,397		6,661
Total share-based compensation expense	$	5,637	$	2,632	$	11,093	$	4,444	$	11,860

In September 2015, the Company adopted an employee share purchase plan (“ESPP”) to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. In the United States, the ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code and the provisions of the ESPP will be construed in a manner consistent with the requirements of such section. The Company intends to begin offerings under the ESPP on August 1, 2016. As of June 30, 2016, 1,667,785 ordinary shares were available to be purchased by eligible employees under the ESPP and no shares have been offered under the ESPP.

- 9 -

NOTE 7: SUPPLEMENTAL INFORMATION

The Company operates in a single reportable segment.

The following table presents long-lived assets by location:

	June 30,		December 31,
	2016		2015
	Unaudited		Audited
United States	$	5,959	$	6,600
Switzerland		6,385		4,204
Israel		1,862		1,376
Others		457		401
Total	$	14,663	$	12,581

The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:

	Three months ended June 30,				Six months ended June 30,				Year ended December 31,
	2016		2015		2016		2015		2015
	Unaudited				Unaudited				Audited
United States	$	16,122	$	6,190	$	28,135	$	11,164	$	30,961
Europe, Japan and others		1,797		353		2,837		587		2,126
Total	$	17,919	$	6,543	$	30,972	$	11,751	$	33,087

NOTE 8: LONG-TERM LOAN, NET OF DISCOUNT AND ISSUANCE COSTS

In January 2015, the Company entered into a five-year term loan agreement and related documents (the “Term Loan Credit Facility”) with a lender to draw up to $100,000. In January 2015, the Company drew $25,000 from the lender. The Company had the option to draw the remaining $75,000 at its option at any time through June 30, 2016. On June 30, 2016, the Company provided to the lender a drawdown notice for the remaining $75,000, and it received funds in July 2016. Following the July 2016 closing, our material outstanding indebtedness under the Term Loan Credit Facility is $100 million.

Interest on the outstanding loan is 10% annually, payable quarterly in arrears. In addition, there is a 1.5% funding fee payable on the amount drawn on the funding date, a 0.75% pay-down fee on all principal amount repayments to be paid on the date such payments of principal are made and a pre-payment fee of 3.0%, 2.0% or 1.0% if the Company prepays outstanding loan amounts prior to the first, second or third year, respectively, from the initial funding date. The entire outstanding principal loan is due on January 2020. The loan is secured by a first priority security interest in substantially all assets of the Company. The Term Loan Credit Facility sets forth certain affirmative and negative covenants with which the Company must comply on a quarterly basis through the term of the loan. As of June 30, 2016, the Company was in compliance with such covenants.

The total discount of $491 and additional issuance costs of $1,739 are presented net of the loan and are amortized to interest expense over the five year term of the loan using the effective interest method.

NOTE 9: IMPAIRMENT OF FIELD EQUIPMENT

The Company received U.S. Food and Drug Administration approval on its premarket approval supplement application to market its second generation Optune System in the United States on July 13, 2016. The Company has begun converting patients in the United States from the first generation Optune System to the second generation Optune System and expects to complete the conversion over the next few months. Manufacturing of the first generation Optune System has been terminated. For the three and six months ended June 30, 2016, the Company recorded an impairment loss with respect to the write-off of first generation Optune System field equipment (finished goods and production stage) in the amount of $6,412, including advances for materials purchased and liabilities incurred to vendors of $1,582 that are not recoverable, presented in cost of revenues. The Company does not expect the conversion to result in an additional material impairment charge in the future.

- 10 -

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to provide information to assist you in better understanding and evaluating our financial condition and results of operations. We encourage you to read this MD&A in conjunction with our consolidated financial statements for the period ended June 30, 2016 included in Part I, Item 1 of this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth under Part I, Item 1A, “Risk Factors”, of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the “2015 10-K”), our actual results may differ materially from those anticipated in these forward-looking statements. References to the words “we,” “our,” “us,” and the “Company” in this report refer to NovoCure Limited, including its consolidated subsidiaries.

Overview

We are a commercial-stage oncology company developing a novel, proprietary therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on key molecules inside cancer cells, disrupting the basic machinery necessary for normal cell division, leading to cancer cell death. Physicians have typically treated patients with solid tumors using one or a combination of three principal treatment modalities—surgery, radiation and pharmacological therapies. Despite meaningful advancements in each of these modalities, a significant unmet need to improve survival and quality of life remains. We believe we will establish TTFields as a new treatment modality for a variety of solid tumors that increases survival without significantly increasing side effects when used in combination with other cancer treatment modalities.

We were founded in 2000 and operated as a development stage company through December 31, 2011. We initially received U.S. Food and Drug Administration (“FDA”) approval for Optune, our first commercial TTFields delivery system, in 2011 for use as a monotherapy treatment for adult patients with glioblastoma brain cancer (“GBM”) following confirmed recurrence after chemotherapy. In November 2014, our phase 3 pivotal trial of Optune in combination with chemotherapy for patients with newly diagnosed GBM met its endpoints after a pre-specified interim analysis showed significant improvements in both progression free and overall survival. In October 2015, we received FDA approval to market Optune for the treatment of adult patients with newly diagnosed GBM in combination with temozolomide, a chemotherapy drug. In July 2016, Optune was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Central Nervous Systems Cancers for newly diagnosed GBM. Optune plus temozolomide is now a Category 2A recommendation following standard brain radiation therapy with concurrent temozolomide, and is now a standard treatment option for newly diagnosed patients with GBM.

We have built a commercial organization and launched Optune in the United States, Germany, Switzerland and Japan, which we refer to as our currently active markets. As we enter each new market, our commercial activities focus initially on establishing the required in-market infrastructure, certifying physicians to prescribe Optune and obtaining a defined reimbursement pathway. Once established, our commercial efforts turn to increasing adoption.

In December 2015, we submitted a partial amendment application to the Japanese Pharmaceuticals and Medical Devices Agency in connection with our application for approval of Optune for the treatment of patients with newly diagnosed GBM. We hope to receive Japanese Ministry of Health, Labour and Welfare (“MHLW”) approval for this indication in late 2016. The MHLW approved the use of Optune to treat patients with recurrent GBM in March 2015. We plan to wait until we receive MHLW approval for the use of Optune to treat patients with newly diagnosed GBM before we submit an application for public reimbursement of Optune in Japan.

We continue to invest in the improvement of Optune to enhance ease of use for patients. A second generation Optune System that is less than half the weight and size of the first generation Optune System was launched in Europe in the fourth quarter of 2015. We received FDA approval on the premarket approval supplement application to market the second generation Optune System in the United States in July 2016 and are in the process of converting all patients to the second generation Optune System.

We have researched the biological effects of TTFields extensively. Because TTFields are delivered regionally, act only on mitotic cells and are tuned to target cells of a specific size, there is minimal damage to healthy cells. We believe our pre-clinical and clinical research demonstrates that TTFields’ mechanism of action affects fundamental aspects of cell division and can have broad applicability across a variety of solid tumors. We have demonstrated in pre-clinical studies that TTFields can offer additive or synergistic benefits in combination with radiation, chemotherapy, and immunotherapy, which may lead to greater efficacy than radiation, chemotherapy, and immunotherapy alone, without appearing to increase the side effects of the other cancer treatments. In addition to our clinical and commercial progress in GBM, we are currently planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (“NSCLC”), pancreatic cancer, ovarian cancer and mesothelioma.

Results from the first cohort of our PANOVA trial, a phase 2 pilot trial in advanced pancreatic adenocarcinoma examining TTFields in combination with chemotherapy, were presented at the American Society of Clinical Oncology (“ASCO”) Gastrointestinal Cancers

- 11 -

Symposium in January 2016, with additional subgroup analyses presented at the ASCO Annual Meeting in June 2016. The first cohort was designed to test the feasibility, safety and preliminary efficacy of TTFields in combination with gemcitabine, a chemotherapy drug, and included 20 patients with advanced pancreatic cancer whose tumors could not be removed surgically and who had not received chemotherapy or radiation therapy prior to the clinical trial. Efficacy results based on the 20 patients in the first cohort showed that progression free survival (“PFS”) and overall survival (“OS”), of patients treated with TTFields combined with gemcitabine were more than double those of gemcitabine-treated historical controls. Of the 20 patients in the first cohort of the trial, 13 had distant metastases and seven had locally advanced unresectable disease. The median OS for all patients was 14.9 months. Median OS was longer than 15 months in locally advanced patients with 86% of patients alive at end of follow up. Patients with metastatic disease experienced a median OS of 8.3 months. The one-year survival rate was 55%; 86% in locally advanced and 40% in metastatic disease. Adverse events reported in this combination study were comparable to those reported with gemcitabine alone, suggesting minimal added toxicities due to TTFields.

Following the approval of nab-paclitaxel, a taxane-based chemotherapy, for the treatment of advanced pancreatic cancer, the PANOVA study was expanded to include 20 additional patients treated with TTFields in combination with nab-paclitaxel and gemcitabine. We finished enrollment of the second patient cohort in May 2016 and, with an expected six month follow-up period, we anticipate that phase 2 pilot data will be available in December 2016.

We also finished enrollment in our INNOVATE trial, a phase 2 pilot trial in recurrent ovarian cancer examining TTFields in combination with weekly paclitaxel, in May 2016 and, with an expected six month follow-up period, we anticipate that phase 2 pilot data will be available in December 2016.

In May 2016, we received FDA approval of our IDE application to initiate the METIS trial, a phase 3 pivotal trial studying radiosurgery plus TTFields compared to radiosurgery alone for brain metastases from non-small cell lung cancer. Given the recent advances in our METIS trial, in July 2016 we closed enrollment for COMET, our phase 2 pilot trial in brain metastases.

The table below presents the current status of our clinical pipeline. We anticipate expanding our clinical pipeline over time to study the safety and efficacy of TTFields for additional solid tumor indications.

We own all commercialization rights to TTFields in oncology. Our robust global patent and intellectual property portfolio consists of over 50 issued patents, with numerous additional patent applications pending worldwide. We believe we will maintain exclusive rights to market TTFields for all solid tumor indications in our key markets through the life of our patents.

Financial Overview. We expect to continue to incur significant expenses and operating losses for at least the next several years. We expect our research, development and clinical trials expenses to increase in connection with our ongoing activities, and as additional indications enter late-stage clinical development. In addition, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We may need additional funding to support the continuation of our operating activities. Until we can generate substantial revenues (which may not occur), we expect to finance our cash needs through our existing cash, cash equivalents, and short-term investments, equity issuances or additional debt, and possibly also from collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. We will need to generate significant revenues to achieve profitability, and we may never do so.

Critical accounting policies and estimates

In accordance with U.S. GAAP, in preparing our financial statements, we must make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements

- 12 -

and the reported amounts of net revenues and expenses during the reporting period. We develop and periodically change these estimates and assumptions based on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates.

The critical accounting policies requiring estimates, assumptions and judgments that we believe have the most significant impact on our consolidated financial statements can be found in our 2015 10-K. There have been no material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates described in our 2015 10-K.

Results of Operations

We account for revenue when cash is collected and all other revenue recognition criteria have been met. We report certain operating statistics to provide additional insight into the commercial performance of Optune in our currently active markets.

Prescriptions are a leading indicator of Optune demand. The conversion of prescriptions to new patients is driven by the prescription fill rate and the time to fill. The prescription fill rate for the twelve months ended June 30, 2016 was 75%. The increase or decrease in active patients in any given period reflects the number of new patients starting on therapy, driven by filled prescriptions, as compared to the number of patients discontinuing therapy, which reflects the treatment duration for patients starting in prior periods.

The following table includes certain commercial operating statistics for and as of the end of the periods presented.

	Three months ended June 30,				Six months ended June 30,
Operating statistics	2016		2015		2016		2015
Prescriptions received in period (1)
United States		547		390		1,231		801
Germany, Switzerland and other EMEA markets (2) (4)		110		38		181		64
Japan (2)		-		-		-		-
		657		428		1,412		865
Active patients at period end (3)
United States		736		391		736		391
Germany, Switzerland and other EMEA markets (2) (4)		155		34		155		34
Japan (2)		-		-		-		-
		891		425		891		425

(1)

A “prescription received” is a commercial order for Optune that is received from a physician certified to treat patients with TTFields therapy for a patient not previously on TTFields therapy. Orders to renew or extend treatment are not included in this total. In the future, we may have regulatory approvals and commercial programs for multiple clinical indications, at which time we will recognize a commercial order as a prescription for the same patient for each clinical indication treated. For example, in the future, a patient may have a prescription for the treatment of lung cancer and a prescription for the treatment of brain metastases from the lung cancer.

(2)	As we enter each new market, our commercial activities focus initially on establishing the required in-market infrastructure, certifying physicians to prescribe Optune and obtaining a defined reimbursement pathway. Once established, our commercial efforts turn to increasing adoption.

(3)	An “active patient” is a patient who is on TTFields therapy under a commercial prescription order as of the measurement date, including patients who may be on a temporary break from treatment and who plan to resume treatment in less than 60 days.

(4)	EMEA refers to Europe, the Middle East and Africa.

We view our operations and manage our business in one operating segment. For the three and six months ended June 30, 2016, our net revenues were $17.9 million and $31.0 million, respectively, and our net losses were $40.6 million and $76.1 million, respectively. Our net loss for the three and six month period ended June 30, 2016 includes $5.6 million and $11.1.million, respectively, in non-cash share-based compensation expense. As of June 30, 2016, we had an accumulated deficit of $464.1 million.

Three months ended June 30, 2016 compared to three months ended June 30, 2015

	Three Months Ended June 30,
	2016		2015		Change		% Change
Net revenues	$	17,919	$	6,543	$	11,376		174	%

- 13 -

Net revenues. Substantially all of our revenues are derived from patients using our TTFields delivery system, marketed as Optune in our currently active markets. We charge patients or their third-party healthcare payers directly on a monthly basis and bear the financial risk of securing payment in the United States and Europe.

We account for revenue when cash is collected and other revenue recognition criteria have been met as we have not yet built up sufficient history with each individual third-party payer to reliably estimate their individual payment patterns. As a result, revenue in the reported periods is a mixture of amounts collected from patients using Optune in the period and amounts collected for use of Optune in prior periods.

Net revenues increased by $11.4 million, or 174%, to $17.9 million for the three months ended June 30, 2016 from $6.5 million for the three months ended June 30, 2015. The increase was primarily due to an increase of $9.9 million in commercial sales of Optune in the United States, driven by an increase in Optune adoption, as well as to an increase of $1.4 million in commercial sales of Optune in our other currently active markets, also driven by an increase in Optune adoption.

Cost of revenues. Our cost of revenues is comprised primarily of (i) cost of the disposable transducer arrays purchased from third-party manufacturers, (ii) depreciation expense for field equipment, including the electric field generator used by patients and (iii) personnel, warranty and overhead costs such as facilities, freight and depreciation of property, plant and equipment associated with managing our inventory, warehousing and order fulfillment functions. Our cost of revenues (excluding the impairment of field equipment described below) increased by $5.0 million, or 106%, to $9.8 million for the three months ended June 30, 2016 from $4.8 million for the three months ended June 30, 2015. The change was due to an increase in Optune adoption which caused a $2.7 million increase in the cost of transducer array shipments and a $0.4 million increase in field equipment depreciation expenses. In addition, there was a $1.7 million increase in personnel costs to establish the infrastructure necessary to support an increasing volume of shipments.

We received FDA approval on our PMA supplement application to market our second generation Optune System in the United States in July 2016. We have begun converting patients in the United States from the first generation Optune System to the second generation Optune System and expect to complete the conversion over the next few months. Manufacturing of the first generation Optune System has been terminated. For the three months ended June 30, 2016, we recorded an impairment loss with respect to the write-off of our first generation Optune System field equipment (finished goods and production stage) in the amount of $6.4 million that is not recoverable and is presented in cost of revenues. We do not expect the conversion to result in an additional material impairment charge in the future.

Operating Expenses. Our operating expenses consist of research, development and clinical trials, sales and marketing and general and administrative expenses. Personnel costs are a significant component for each category of operating expenses and consist of wages, benefits and bonuses. Personnel costs also include share-based compensation.

	Three Months Ended June 30,
	2016		2015		Change			% Change
Research, development and clinical trials	$	11,318	$	12,765	$	(1,447	)		-11	%
Sales and marketing		14,598		8,866		5,732			65	%
General and administrative		13,031		7,368		5,663			77	%
Total operating expenses	$	38,947	$	28,999	$	9,948
Non-cash expenses:
Share-based compensation expense	$	5,467	$	2,626	$	2,841			108	%
Other non-cash expenses		709		196		513			262	%
Total non-cash expenses	$	6,176	$	2,822	$	3,354			119	%

Total operating expenses, net of non-cash expenses	$	32,771	$	26,177	$	6,594			25	%

Research, development and clinical trials expenses. Research, development and clinical trials expenses decreased by $1.5 million, or 11%, to $11.3 million for the three months ended June 30, 2016 from $12.8 million for the three months ended June 30, 2015. The change was primarily due to a decrease of $2.5 million in clinical trial expenses primarily related to the conclusion of our EF-14 trial, and a decrease of $0.5 million in clinical trial expenses primarily related to clinical education and investigator-sponsored trials, partially offset by an increase of $1.2 million in personnel costs (including an increase of $0.2 million in share-based compensation) and clinical trial expenses for our other ongoing phase 2 pilot trials.

- 14 -

Sales and marketing expenses. Sales and marketing expenses increased by $5.7 million, or 65%, to $14.6 million for the three months ended June 30, 2016 from $8.9 million for the three months ended June 30, 2015. The change was primarily due to an increase of $3.6 million in personnel costs (including an increase of $0.8 million in share-based compensation) and an increase of $2.0 million in marketing expenses, reflecting our increased commercial operations in the United States and Germany and our ongoing efforts to establish commercial operations in Switzerland and Japan.

General and administrative expenses. General and administrative expenses increased by $5.7 million, or 77%, to $13 million for the three months ended June 30, 2016 from $7.3 million for the three months ended June 30, 2015. The change was primarily due to an increase of $3.4 million in personnel costs (including an increase of $1.9 million in share-based compensation) and $1.8 million in professional services to support our enterprise resource planning system implementation and public company-related activities.

Financial expenses, net. Financial expenses, net primarily consists of interest expense and related debt issuance costs under our Loan and Security Agreement dated as of January 7, 2015, between us, as borrower, and Biopharma Secured Investments III Holdings Cayman LP, as lender (the “Term Loan Credit Facility”), interest income from cash balances and short-term investments and gains (losses) from foreign currency transactions.

Three Months Ended

June 30,

2016

2015

Change

% Change

Income tax expenses

2,820

1,275

1,545

121

Income taxes. Income taxes increased by $1.5 million to $2.8 million for the three months ended June 30, 2016 compared to the same period of 2015. The change was primarily attributable to an increase in the statutory tax provisions for Switzerland and the United States as well as an increase in our provision for uncertain tax positions.

Six months ended June 30, 2016 compared to six months ended June 30, 2015

Net revenues increased by $19.2 million, or 164%, to $ 31.0 million for the six months ended June 30, 2016 from $11.8 million for the six months ended June 30, 2015. The increase was primarily due to an increase of $17.0 million in commercial sales of Optune in the United States, driven by an increase in Optune adoption as well as to an increase of $2.2 million in commercial sales of Optune in our other currently active markets, also driven by an increase in Optune adoption.

Cost of revenues. Our cost of revenues is comprised primarily of (i) cost of the disposable transducer arrays purchased from third-party manufacturers, (ii) depreciation expense for field equipment, including the electric field generator used by patients and (iii) personnel, warranty and overhead costs such as facilities, freight and depreciation of property, plant and equipment associated with managing our inventory, warehousing and order fulfillment functions. Our cost of revenues (excluding the impairment of field equipment described below) increased by $9.1 million, or 106%, to $17.8 million for the six months ended June 30, 2016 from $8.7 million for the six months ended June 30, 2015. The change was due to an increase in Optune adoption, which caused a $5.0 million increase in the cost of transducer array shipments and a $0.7 million increase in field equipment depreciation expenses. In addition, there was a $3.4 million increase in personnel costs to establish the infrastructure necessary to support an increasing volume of shipments.

We received FDA approval on our PMA supplement application to market our second generation Optune System in the United States in July 2016. We have begun converting patients in the United States from the first generation Optune System to the second generation Optune System and expect to complete the conversion over the next few months. Manufacturing of the first generation Optune System has been terminated. For the six months ended June 30, 2016, we recorded an impairment loss with respect to the write-off of first generation Optune System field equipment (finished goods and production stage) in the amount of $6.4 million that is

- 15 -

not recoverable and is presented in cost of revenues. We do not expect the conversion to result in an additional material impairment charge in the future.

	Six Months Ended June 30,
	2016		2015		Change		% Change
Research, development and clinical trials	$	22,763	$	22,692	$	71		0	%
Sales and marketing		27,906		15,221		12,685		83	%
General and administrative		25,287		14,343		10,944		76	%
Total operating expenses	$	75,956	$	52,256	$	23,700
Non-cash expenses:
Share-based compensation expense	$	10,782	$	4,425	$	6,357		144	%
Other non-cash expenses		1,315		367		948		258	%
Total non-cash expenses	$	12,097	$	4,792	$	7,305		152	%

Total operating expenses, net of non-cash expenses	$	63,859	$	47,464	$	16,395		35	%

Research, development and clinical trials expenses. Research, development and clinical trials expenses increased by $0.1 million, or 0.3%, to $22.8 million for the six months ended June 30, 2016 from $22.7 million for the six months ended June 30, 2015. The change was primarily due to an increase of $2.7 million in personnel costs (including an increase of $0.6 million in share-based compensation) and clinical trial expenses for our ongoing phase 2 pilot trials, offset by a decrease of $2.6 million in clinical trial materials and expenses primarily related to the conclusion of our EF-14 trial.

Sales and marketing expenses. Sales and marketing expenses increased by $12.7 million, or 83%, to $27.9 million for the six months ended June 30, 2016 from $15.2 million for the six months ended June 30, 2015. The change was primarily due to an increase of $7.3 million in personnel costs (including an increase of $1.7 million in share-based compensation) and an increase of $3.5 million in marketing expenses, reflecting our increased commercial operations in the United States and Germany and our ongoing efforts to establish commercial operations in Switzerland and Japan.

General and administrative expenses. General and administrative expenses increased by $10.9 million, or 76%, to $25.3 million for the six months ended June 30, 2016 from $14.4 million for the six months ended June 30, 2015. The change was primarily due to an increase of $7.0 million in personnel costs (including an increase of $4.1 million in share-based compensation), and an increase of $2.7 million in professional services to support our enterprise resource planning system implementation and public company-related activities.

Financial expenses, net. Financial expenses, net primarily consists of interest expense and related debt issuance costs under our Term Loan Credit Facility, interest income from cash balances and short-term investments and gains (losses) from foreign currency transactions.

Six Months Ended

June 30,

2016

2015

Change

% Change

Income tax expenses

5,770

2,011

3,759

187

Income taxes. Income taxes increased by $3.8 million to $5.8 million for the six months ended June 30, 2016. The change was primarily attributable to an increase in the statutory tax provisions for Switzerland and the United States as well as an increase in our provision for uncertain tax positions.

Liquidity and Capital Resources

Sources of Liquidity

Since inception, we have financed our operations primarily through the issuance and sale of equity and the proceeds from long-term loans. As of June 30, 2016, we had received a total of $615.6 million from these activities. As of June 30, 2016, we had an accumulated deficit of $464.1 million since inception.

- 16 -

Our net losses were $76.1 million for the six months ended June 30, 2016 and $111.6 million for the year ended December 31, 2015. Our net losses primarily resulted from costs incurred in connection with our pre-clinical and clinical trial programs, costs incurred in our commercial launch efforts, and general and administrative costs necessary to operate as a multi-national oncology business.

As of June 30, 2016, we had $80.9 million of cash and cash equivalents and $120.0 million of short-term investments. We believe our cash and cash equivalents and short term investments as of June 30, 2016, in addition to the $75.0 million that we drew under our Term Loan Credit Facility in July 2016, are sufficient for our operations for at least the next 12 months based on our existing business plan and our ability to control the timing of significant expense commitments. We expect that our research, development and clinical trials expenses, sales and marketing expenses and general and administrative expenses will continue to increase over the next several years. As a result, we may need to raise additional capital in the future to fund our operations.

	Six Months Ended June 30,
	2016			2015
	(in thousands)
Net cash used in operating activities	$	(60,371	)	$	(51,657	)
Net cash provided by (used in) investing activities		20,820			(16,622	)
Net cash provided by financing activities		943			117,174
Net increase (decrease) in cash and cash equivalents		(38,608	)		48,895
Effect of exchange rates on cash and cash equivalents		56			-
Changes in short-term investments (included in investing activities)		(30,022	)		11,997
Net increase (decrease) in cash, cash equivalents and short-term investments	$	(68,574	)	$	60,892

Operating activities

Net cash used in operating activities primarily represents our net loss for the periods presented. Adjustments to net loss for non-cash items include depreciation, share-based compensation, accrued interest and impairments. Operating cash flows are also impacted by changes in operating assets and liabilities, principally inventories, prepaid expenses, trade payables and accrued expenses.

Net cash used in operating activities was $60.4 million for the six months ended June 30, 2016, as compared to $51.7 million for the six months ended June 30, 2015, reflecting a net loss of $76.1 million and a change of $4.3 million in our net operating assets and liabilities, partially offset by non-cash charges of $19.9 million, which includes $6.4 million of field equipment impairment.

The change in our net operating assets and liabilities was primarily the result of an increase in our inventories of $7.6 million necessary to meet anticipated demand offset by an increase in trade payables of $4.1 million, other payables of $0.8 million and other receivables of $2.2 million. Non-cash charges included $11.1 million of share-based compensation, $6.4 million of field equipment impairment and $2.5 million of depreciation.

Investing activities

Our investing activities consist primarily of capital expenditures to purchase property and equipment and field equipment, as well as investments in and redemptions of our short-term investments.

Net cash provided by investing activities was $20.8 million in the six months ended June 30, 2016 attributable to our receipt of $150.0 million from the maturity of short-term investments, partially offset by the purchase of $120.0 million of new short-term investments, purchases of $3.3 million of property and equipment and purchases of $6.1 million of field equipment. Net cash used in investing activities for the same period in 2015 was $16.6 million, attributable to the receipt of $47.0 million from the maturity of short-term investments, offset by the purchase of $59.0 million of short-term investments, purchases of $2.4 million of property and equipment and purchases of $2.2 million of field equipment.

Financing activities

To date, our primary financing activities have been the sale of equity and the proceeds from long-term loans.

Net cash provided by financing activities consist primarily of approximately $1.0 million received from the exercise of warrants and options by investors and employees during the six months ended June 30, 2016. Net cash provided by financing activities was $117.2

- 17 -

million in the same period of 2015, attributable to a draw under our Term Loan Credit Facility and consideration received from the sale of Series J preferred shares in the second quarter of 2015.

Our material outstanding indebtedness consists of our Term Loan Credit Facility, which provides for up to $100.0 million of borrowings in up to four draws, the first of which was made on January 30, 2015 in the amount of $25.0 million of principal resulting in $23.8 million of proceeds net of discount and issuance costs, net. On June 30, 2016, we provided to the lender a drawdown notice for the remaining $75.0 million. In July 2016, we closed on a draw in the amount of $75.0 million of principal, resulting in $72.9 million of proceeds net of discount and issuance costs, net. Following the July 2016 closing, our material outstanding indebtedness under the Term Loan Credit Facility is $100.0 million.

Interest on the outstanding loan is 10% annually, payable quarterly in arrears. As of June 30, 2016, the aggregate principal balance of amounts outstanding under the Term Loan Credit Facility was approximately $25.0 million. We may prepay the term loans, in whole, at any time, and must prepay in the event of a change of control, in each case, subject to a pay-down fee, prepayment premium and/or make-whole payment. The funding fee payable on the amount drawn on the funding date is 1.5%, the placement fee payable on the amount drawn on the funding date is 1.25%, the pay-down fee on all principal payments to be paid on the date such payments are made is 0.75% and the pre-payment fee if we prepay outstanding loan amounts prior to the first, second or third year from the initial funding date is 3.0%, 2.0% or 1.0%, respectively.

All obligations under the Term Loan Credit Facility are guaranteed by certain of our current and future domestic direct and indirect subsidiaries. In addition, the obligations under the Term Loan Credit Facility are secured by a first-priority security interest in substantially all of the property and assets of, as well as the equity interests owned by, us and the other guarantors.

The Term Loan Credit Facility has a minimum liquidity covenant, which is tested quarterly. In addition, we must meet certain pro forma net sales requirements. The Term Loan Credit Facility contains other customary covenants.

Contractual Obligations and Commitments

There were no material changes in our commitments under contractual obligations during the three months ended June 30, 2016.

The total amount of unrecognized tax benefits for uncertain tax positions was $2.2 million and $1.6 million at June 30, 2016 and December 31, 2015, respectively. Payment of these obligations would result from settlements with taxing authorities. We do not expect a significant tax payment related to these obligations within the next year.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements as defined under SEC rules.

JOBS Act Election

The Jumpstart our Business Startups Act of 2012, or the JOBS Act, permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have irrevocably elected to “opt out” of the exemption for the delayed adoption of certain accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2016. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated,

- 18 -

can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2016, our Chief Executive Officer and Chief Financial Officer have concluded that, as of June 30, 2016, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting during the quarter ended June 30, 2016, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

- 19 -

PART II—OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

For the six months ended June 30, 2016, warrants to purchase 220,316 ordinary shares with an exercise price of $3.59 were exercised, resulting in the issuance of 220,316 ordinary shares, and warrants to purchase 975,644 and 888,219 ordinary shares with exercise prices of $18.09 and $3.59 per share, respectively, were cashlessly exercised, resulting in the issuance of 950,637 ordinary shares. We believe that each of these instances was exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on Regulation S under the Securities Act, under Section 4(a)(2) of the Securities Act regarding transactions not involving a public offering and under Rule 701 promulgated under the Securities Act.

Item 5. Other Information

Term Loan Credit Facility Draw

In January 2015, we entered into a five-year term loan agreement (the “Term Loan Credit Facility”) with a lender to draw up to $100.0 million. In January 2015, we drew $25.0 million under the Term Loan Credit Facility. We had the option to draw the remaining $75.0 million at any time through June 30, 2016. On June 30, 2016, we provided to the lender a drawdown notice for $75.0 million in accordance with the Term Loan Credit Facility. In July 2016, we closed on a draw in the amount of $75.0 million of principal, resulting in $72.9 million of proceeds net of discount and issuance costs, net. Following the July 2016 closing, our material outstanding indebtedness under the Term Loan Credit Facility is $100.0 million.

Interest on the outstanding loan is 10% annually, payable quarterly in arrears. In addition, there is a 1.5% funding fee payable on the amount drawn on the funding date, a 0.75% pay-down fee on all principal amount repayments to be paid on the date such payments of principal are made and a pre-payment fee of 3.0%, 2.0% or 1.0% if we prepay outstanding loan amounts prior to the first, second or third year, respectively, from the initial funding date. The entire outstanding principal loan is due on January 2020. The loan is secured by a first priority security interest in substantially all of our assets. The Term Loan Credit Facility sets forth certain affirmative and negative covenants with which we must comply on a quarterly basis through the term of the loan.

Lead Independent Director

On May 4, 2016, the Company’s Board of Directors appointed William A. Vernon as lead independent director. Following Mr. Vernon’s appointment, on July 27, 2016, the Board of Directors amended the Company’s Non-Employee Director Compensation Plan to include annual compensation in the amount of $25,000 for the lead independent director.

- 20 -

Item 6. Exhibits

EXHIBIT INDEX

Exhibit		Incorporated by Reference			Filed
Number	Exhibit Description	Form	Date	Number	Herewith

10.1	Non-Employee Director Compensation Program				X
31.1	Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended				X
31.2	Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended				X
32.1*	Certification of Principal Executive Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350				X
32.2*	Certification of Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350				X
101.INS	XBRL Instance Document				X
101.SCH	XBRL Taxonomy Extension Schema Document				X
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document				X
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document				X
101.LAB	XBRL Taxonomy Extension Label Linkbase Document				X
101.PRE	XBRL Extension Presentation Linkbase Document				X

The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of NovoCure Limited under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.

- 21 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		NovoCure Limited

Date: July 28, 2016		/s/ Wilco Groenhuysen
		Wilco Groenhuysen
		Chief Financial Officer
		(principal financial and accounting officer and duly authorized officer)

- 22 -

EX-10 2 nvcr-ex101_312.htm EX-10.1 nvcr-ex101_312.htm

Exhibit 10.1

NOVOCURE LIMITED

Non-Employee Director Compensation Program

1. General. This Non-Employee Director Compensation Program (this “Program”) is adopted by the Board of Directors (the “Board”) of NovoCure Limited, a public limited company incorporated under the laws of Jersey, Channel Islands (the “Company”). For purposes of this Program, a “Non-Employee Director” shall mean director of the Company who is an “independent director” pursuant to NASDAQ Listing Rule 5605(a)(2).

2. Annual Cash Compensation. Each Non-Employee Director shall be entitled to an annual cash retainer fee of $45,000 (the “Annual Retainer”). In addition to the Annual Retainer payments, Non-Employee Directors will be entitled to an annual cash retainer of (a) $25,000 for serving as the chairperson of the Board’s Audit Committee (the “Audit Committee”), (b) $15,000 for serving as the chairperson of the Board’s Compensation Committee (the “Compensation Committee”), (c) $10,000 for serving as the chairperson of the Board’s Nominating and Governance Committee (the “Nominating Committee”), and (d) $25,000 for serving as the lead independent director of the Board. In addition to the Annual Retainer payments, Non-Employee Directors will be entitled to an annual cash retainer of (a) $15,000 for serving as a member of the Board’s Audit Committee, (b) $7,500 for serving as a member of the Compensation Committee, and (c) $5,000 for serving as a member of the Nominating Committee. The Annual Retainer, any annual retainer for serving as the chairperson of a committee and any annual retaining for serving as a member of a committee shall be pro-rated for any partial period of service. All cash compensation payable to Non-Employee Directors shall be payable in arrears on a quarterly basis within thirty days following the end of each fiscal quarter.

3. Annual Equity Awards to Non-Employee Directors. On the date of each annual general meeting of the Company’s shareholders (“Annual Meeting”) or such other date duly authorized by the Compensation Committee or the Board, the Board may consider a grant of share options under the NovoCure Limited 2015 Omnibus Incentive Plan (the “Plan”) and a related award agreement to each Non-Employee Director immediately following the Annual Meeting (or such other duly authorized date, as appropriate). Such grant of share options shall be in an amount determined by the Board or Compensation Committee, in its sole discretion (each, an “Annual Equity Award”), provided that such Annual Equity Awards shall not exceed options to purchase 23,600 ordinary shares of the Company (as such number of ordinary shares may be adjusted pursuant to Section 4.2 of the Plan). It is intended that the Non-Employee Directors elected or appointed to the Board between Annual Meetings will receive an Annual Equity Award for options to purchase a number of ordinary shares of the Company based on that percentage of such annual share option grant that equals the percentage of the year (beginning from the date of such election or appointment) remaining until the next Annual Meeting (assuming that such next Annual Meeting occurs on the anniversary of the preceding Annual Meeting). It is intended that any such Annual Equity Award (or pro-rated portion) will vest ratably on the anniversary of the Annual Equity Award’s grant date.

4. Effective Date. This Program shall be effective upon the effectiveness of the registration statement on Form S-1 to be filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended, in connection with the initial public offering of the ordinary shares of the Company.

5. Expense Reimbursements. Each Non-Employee Director will be entitled to reimbursement for all reasonable and documented expenses incurred in the performance of his or her duties as a director of the Company pursuant to the terms of any applicable Company expense reimbursement policy that is in effect from time to time.

6. Program Subject to Amendment, Modification and Termination. This Program may be amended, modified or terminated by the Board or Compensation Committee at any time, or from time to time, in their sole discretion. No Non-Employee Director shall have any rights hereunder unless and until an Award (as defined in the Plan) is actually granted under the Plan. Without limiting the generality of the foregoing, the Board and Compensation Committee hereby expressly reserve the authority to terminate this Program during any year up and until the election of directors at a given Annual Meeting.

7. Taxes. The Company is not responsible for the tax consequences under federal, foreign, provincial, state or local law with respect to any compensation, fees, equity awards or other payments made pursuant to this Program.

Revised on July 27, 2016

EX-31 3 nvcr-ex311_6.htm EX-31.1 nvcr-ex311_6.htm

Exhibit 31.1

CERTIFICATIONS

I, Asaf Danziger, certify that:

I have reviewed this Quarterly Report on Form 10-Q of NovoCure Limited;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: July 28, 2016

/s/ Asaf Danziger

Asaf Danziger

Chief Executive Officer and Director

(Principal Executive Officer)

EX-31 4 nvcr-ex312_10.htm EX-31.2 nvcr-ex312_10.htm

Exhibit 31.2

CERTIFICATIONS

I, Wilco Groenhuysen, certify that:

I have reviewed this Quarterly Report on Form 10-Q of NovoCure Limited;

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: July 28, 2016

/s/ Wilco Groenhuysen

Wilco Groenhuysen

Chief Financial Officer

(Principal Accounting and Financial Officer)

EX-32 5 nvcr-ex321_7.htm EX-32.1 nvcr-ex321_7.htm

Exhibit 32.1

NOVOCURE LIMITED

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of NovoCure Limited (the "Company") on Form 10-Q for the quarter ended June 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Asaf Danziger, Chief Executive Officer (Principal Executive Officer) of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Asaf Danziger

Asaf Danziger

Chief Executive Officer

(Principal Executive Officer)

Date: July 28, 2016

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff on request.

This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of NovoCure Limited under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

EX-32 6 nvcr-ex322_8.htm EX-32.2 nvcr-ex322_8.htm

Exhibit 32.2

NOVOCURE LIMITED

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of NovoCure Limited (the "Company") on Form 10-Q for the quarter ended June 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Wilco Groenhuysen, Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Wilco Groenhuysen

Wilco Groenhuysen

Chief Financial Officer

(Principal Financial and Accounting Officer)

Date: July 28, 2016

GRAPHIC 7 gu22wyn3vcpe000001.jpg GRAPHIC begin 644 gu22wyn3vcpe000001.jpg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nvcr-20160630.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure 0001645113 2016-01-01 2016-06-30 0001645113 2016-07-26 0001645113 2016-06-30 0001645113 2015-12-31 0001645113 2015-01-01 2015-12-31 0001645113 2016-04-01 2016-06-30 0001645113 2015-04-01 2015-06-30 0001645113 2015-01-01 2015-06-30 0001645113 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001645113 us-gaap:RetainedEarningsMember 2014-12-31 0001645113 2014-12-31 0001645113 us-gaap:CommonStockMember 2014-12-31 0001645113 us-gaap:PreferredStockMember 2014-12-31 0001645113 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0001645113 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0001645113 us-gaap:AdditionalPaidInCapitalMember nvcr:SeriesJPreferredStockMember 2015-01-01 2015-12-31 0001645113 nvcr:SeriesJPreferredStockMember 2015-01-01 2015-12-31 0001645113 us-gaap:PreferredStockMember nvcr:SeriesJPreferredStockMember 2015-01-01 2015-12-31 0001645113 us-gaap:AdditionalPaidInCapitalMember us-gaap:OverAllotmentOptionMember 2015-01-01 2015-12-31 0001645113 us-gaap:OverAllotmentOptionMember 2015-01-01 2015-12-31 0001645113 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2015-01-01 2015-12-31 0001645113 us-gaap:PreferredStockMember 2015-01-01 2015-12-31 0001645113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0001645113 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0001645113 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001645113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001645113 us-gaap:RetainedEarningsMember 2015-12-31 0001645113 us-gaap:CommonStockMember 2015-12-31 0001645113 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-06-30 0001645113 us-gaap:CommonStockMember 2016-01-01 2016-06-30 0001645113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-06-30 0001645113 us-gaap:RetainedEarningsMember 2016-01-01 2016-06-30 0001645113 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0001645113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-06-30 0001645113 us-gaap:RetainedEarningsMember 2016-06-30 0001645113 us-gaap:CommonStockMember 2016-06-30 0001645113 nvcr:SeriesJPreferredStockMember 2016-01-01 2016-06-30 0001645113 us-gaap:OverAllotmentOptionMember 2016-01-01 2016-06-30 0001645113 2016-03-31 0001645113 2015-03-31 0001645113 2015-06-30 0001645113 us-gaap:MaximumMember 2016-01-01 2016-06-30 0001645113 us-gaap:VehiclesMember 2016-01-01 2016-06-30 0001645113 us-gaap:VehiclesMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0001645113 nvcr:WarrantsToPurchaseOrdinaryShareOneMember 2016-01-01 2016-06-30 0001645113 nvcr:WarrantsToPurchaseOrdinaryShareOneMember 2016-06-30 0001645113 nvcr:WarrantsToPurchaseOrdinaryShareTwoMember 2016-01-01 2016-06-30 0001645113 nvcr:WarrantsToPurchaseOrdinaryShareThreeMember 2016-01-01 2016-06-30 0001645113 nvcr:WarrantsToPurchaseOrdinaryShareTwoMember 2016-06-30 0001645113 nvcr:WarrantsToPurchaseOrdinaryShareThreeMember 2016-06-30 0001645113 us-gaap:WarrantMember 2016-01-01 2016-06-30 0001645113 nvcr:TwoThousandFifteenPlanMember 2016-01-01 2016-06-30 0001645113 nvcr:TwoThousandFifteenPlanMember 2016-06-30 0001645113 nvcr:CostOfRevenueMember 2016-04-01 2016-06-30 0001645113 nvcr:CostOfRevenueMember 2015-04-01 2015-06-30 0001645113 nvcr:CostOfRevenueMember 2016-01-01 2016-06-30 0001645113 nvcr:CostOfRevenueMember 2015-01-01 2015-06-30 0001645113 nvcr:CostOfRevenueMember 2015-01-01 2015-12-31 0001645113 us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001645113 us-gaap:ResearchAndDevelopmentExpenseMember 2015-04-01 2015-06-30 0001645113 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0001645113 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-06-30 0001645113 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-12-31 0001645113 nvcr:SalesAndMarketingMember 2016-04-01 2016-06-30 0001645113 nvcr:SalesAndMarketingMember 2015-04-01 2015-06-30 0001645113 nvcr:SalesAndMarketingMember 2016-01-01 2016-06-30 0001645113 nvcr:SalesAndMarketingMember 2015-01-01 2015-06-30 0001645113 nvcr:SalesAndMarketingMember 2015-01-01 2015-12-31 0001645113 us-gaap:GeneralAndAdministrativeExpenseMember 2016-04-01 2016-06-30 0001645113 us-gaap:GeneralAndAdministrativeExpenseMember 2015-04-01 2015-06-30 0001645113 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-06-30 0001645113 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-06-30 0001645113 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-12-31 0001645113 us-gaap:EmployeeStockMember 2016-06-30 0001645113 us-gaap:EmployeeStockMember 2016-01-01 2016-06-30 0001645113 country:US 2016-06-30 0001645113 country:US 2015-12-31 0001645113 country:CH 2016-06-30 0001645113 country:CH 2015-12-31 0001645113 country:IL 2016-06-30 0001645113 country:IL 2015-12-31 0001645113 nvcr:OthersCountriesMember 2016-06-30 0001645113 nvcr:OthersCountriesMember 2015-12-31 0001645113 country:US 2016-04-01 2016-06-30 0001645113 country:US 2015-04-01 2015-06-30 0001645113 country:US 2016-01-01 2016-06-30 0001645113 country:US 2015-01-01 2015-06-30 0001645113 country:US 2015-01-01 2015-12-31 0001645113 nvcr:EuropeJapanAndOthersMember 2016-04-01 2016-06-30 0001645113 nvcr:EuropeJapanAndOthersMember 2015-04-01 2015-06-30 0001645113 nvcr:EuropeJapanAndOthersMember 2016-01-01 2016-06-30 0001645113 nvcr:EuropeJapanAndOthersMember 2015-01-01 2015-06-30 0001645113 nvcr:EuropeJapanAndOthersMember 2015-01-01 2015-12-31 0001645113 nvcr:TermLoanMember 2015-01-01 2015-01-31 0001645113 nvcr:TermLoanMember 2015-01-31 0001645113 nvcr:TermLoanMember 2016-06-30 0001645113 nvcr:TermLoanMember 2016-01-01 2016-06-30 0001645113 us-gaap:DebtInstrumentRedemptionPeriodOneMember nvcr:TermLoanMember 2016-01-01 2016-06-30 0001645113 us-gaap:DebtInstrumentRedemptionPeriodTwoMember nvcr:TermLoanMember 2016-01-01 2016-06-30 0001645113 us-gaap:DebtInstrumentRedemptionPeriodThreeMember nvcr:TermLoanMember 2016-01-01 2016-06-30 0001645113 us-gaap:OtherNoncurrentAssetsMember nvcr:TermLoanMember 2016-06-30 0001645113 nvcr:FirstGenerationOptuneSystemFieldEquipmentMember nvcr:CostOfRevenueMember 2016-04-01 2016-06-30 0001645113 nvcr:FirstGenerationOptuneSystemFieldEquipmentMember nvcr:CostOfRevenueMember 2016-01-01 2016-06-30 10-Q false 2016-06-30 2016 Q2 NVCR Novocure Ltd 0001645113 --12-31 Non-accelerated Filer 85774774

80871000

119423000

119979000

150001000

99000

87000

12534000 10799000

21215000

13594000

234698000

293904000

8813000

6552000

5850000 6029000 82000 79000

1076000

772000

15821000

13432000

250519000

307336000

22007000

16755000

12611000

11872000

34618000

28627000

23292000

23097000

2592000 2057000

3371000

2735000

29255000

27889000

63873000

56516000

652460000

640406000

-1684000

-1505000

-464130000

-388081000

186646000

250820000

250519000

307336000

Unlimited

85774774

83778581

85774774

83778581

17919000

6543000

30972000

11751000

33087000

9797000

4750000

17779000

8647000

20610000

6412000

1710000

1793000

6781000

3104000

12477000

11318000

12765000

22763000

22692000

43748000

14598000

8866000

27906000

15221000

38861000

13031000

7368000

25287000

14343000

33864000

38947000

28999000

75956000

52256000

116473000

-37237000

-27206000

-69175000

-49152000

-103996000

555000

876000

1104000

1467000

3151000

-37792000

-28082000

-70279000

-50619000

-107147000

2820000

1275000

5770000

2011000

4434000

-40612000

-29357000

-76049000

-52630000

-111581000

-0.48

-2.36

-0.90

-4.12

-3.67

85274683

12427442

84843028

12783881

30401603

56000

-235000

235000

1505000

-40321000

-29357000

-76228000

-52630000

-113086000

374375000

-276500000

97875000

13431414

58676017

11860000

2038000 2038000 731665

94599000

4068500

1005210

157534000

7876195

62744517

-62744517

-1505000

-111581000

640406000

-1505000

-388081000

83778581

11093000

961000 961000 1996193

-179000

-76049000

652460000

-1684000

-464130000

85774774

319000

15742000

1407000

588000

2510000

1112000

3153000

6425000

11000

6430000

42000

46000

-637000 307000 719000 672000

5637000

2632000

11093000

4444000

11860000

-39000

88000

-56000

143000

329000

1672000 2079000 2208000 3026000 5088000

4769000

1415000

7621000

5147000

10148000

111000

161000

278000

171000

381000

2321000

3757000

4144000

3085000

6961000

2399000

3237000

756000

518000

3579000

32000

270000

7000

133000

225000

-799000

638000

-753000

581000

-29394000

-23191000

-60371000

-51657000

-99884000

2338000

1808000

3340000

2417000

4667000

4274000 1142000 6100000 2180000 5604000

13000

-40000

12000

33000

26000

2000000

150000000

47000000

104000000

36995000

119728000

58992000

208998000

-6625000

-37905000

20820000

-16622000

-115295000

94599000

252133000

17000

-920000

17000

22886000

294000

19000

15000

35000

31000

63000

5000

904000

16000

961000

19000

2038000

902000

93386000

943000

117174000

276989000

56000

-35061000

32290000

-38552000

48895000

61810000

115932000

74218000

57613000

106508000

1587000

171000

3169000

266000

1489000

1269000

422000

1933000

428000

1688000

<div> NOTE 2: SHORT-TERM INVESTMENTS The Company invests in marketable U.S. Treasury Bills (“T-bills”) that are classified as held-to-maturity securities. The amortized cost and recorded basis of the T-bills are presented as short-term investments in the amount of $119,979 and $150,001 as of June 30, 2016 and December 31, 2015, respectively, and their estimated fair value as of June 30, 2016 and December 31, 2015 was $119,845 and $149,978, respectively.</div>

<div> NOTE 6: EQUITY INCENTIVE PLAN In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the “2015 Plan”). The 2015 Plan replaced the 2013 Share Option Plan.  Under the 2015 Plan, the Company can issue various types of equity compensation awards such as restricted shares, performance shares, restricted stock units, performance units, long-term cash award and other share-based awards.   The options granted under the 2015 Plan generally have a four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are cancelled or forfeited before expiration become available for future grant. As of June 30, 2016, 12,898,636 ordinary shares were available for grant under the 2015 Plan.   A summary of the status of the Company’s option plans as of June 30, 2016 and changes during the period then ended is presented below:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at beginning of year</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,134,829</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.20</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,127,275</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.86</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(825,240</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.21</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(78,243</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.86</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,358,621</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.77</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,586,108</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.86</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,157,637</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.71</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The fair value of share-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions:    <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="4" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="4" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.80%-61.65%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62.5% - 65.8%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.00%-65.80%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.23%-1.88%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75% - 1.9%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.74%-2.05%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</td> </tr> </table></div>   The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and six months ended June 30, 2016 and 2015 and the year ended December 31, 2015 was:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.96%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research, development and clinical trials</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">839</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,602</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,049</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,529</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,349</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">571</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,639</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">979</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,496</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,279</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,427</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,541</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,397</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,661</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,637</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,632</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,093</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,444</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,860</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   In September 2015, the Company adopted an employee share purchase plan (“ESPP”) to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. In the United States, the ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code and the provisions of the ESPP will be construed in a manner consistent with the requirements of such section. The Company intends to begin offerings under the ESPP on August 1, 2016.  As of June 30, 2016, 1,667,785 ordinary shares were available to be purchased by eligible employees under the ESPP and no shares have been offered under the ESPP.</div>

<div> NOTE 8: LONG-TERM LOAN, NET OF DISCOUNT AND ISSUANCE COSTS <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2015, the Company entered into a five-year term loan agreement and related documents (the “Term Loan Credit Facility”) with a lender to draw up to $100,000. In January 2015, the Company drew $25,000 from the lender. The Company had the option to draw the remaining $75,000 at its option at any time through June 30, 2016. On June 30, 2016, the Company provided to the lender a drawdown notice for the remaining $75,000, and it received funds in July 2016. Following the July 2016 closing, our material outstanding indebtedness under the Term Loan Credit Facility is $100 million. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on the outstanding loan is 10% annually, payable quarterly in arrears. In addition, there is a 1.5% funding fee payable on the amount drawn on the funding date, a 0.75% pay-down fee on all principal amount repayments to be paid on the date such payments of principal are made and a pre-payment fee of 3.0%, 2.0% or 1.0% if the Company prepays outstanding loan amounts prior to the first, second or third year, respectively, from the initial funding date. The entire outstanding principal loan is due on January 2020. The loan is secured by a first priority security interest in substantially all assets of the Company. The Term Loan Credit Facility sets forth certain affirmative and negative covenants with which the Company must comply on a quarterly basis through the term of the loan. As of June 30, 2016, the Company was in compliance with such covenants. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total discount of $491 and additional issuance costs of $1,739 are presented net of the loan and are amortized to interest expense over the five year term of the loan using the effective interest method.</div>

<div> Recently Issued Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.   In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.   In April 2016, FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASU 2016-10 covers two specific topics: performance obligations and licensing. This amendment includes guidance on immaterial promised goods or services, shipping or handling activities, separately identifiable performance obligations, functional or symbolic intellectual property licenses, sales-based and usage-based royalties, license restrictions (time, use, geographical) and licensing renewals. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.   In May 2016, FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</div>

<div> Inventories are stated at the lower of cost or market. The weighted average methodology is applied to determine cost. As of June 30, 2016 and December 31, 2015, the Company’s inventories were composed of:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,192</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,518</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in progress</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,031</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,618</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished products</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,992</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,458</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,215</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,594</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> A summary of the status of the Company’s option plans as of June 30, 2016 and changes during the period then ended is presented below:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at beginning of year</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,134,829</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.20</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,127,275</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.86</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(825,240</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.21</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(78,243</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.86</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,358,621</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.77</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,586,108</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.86</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,157,637</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.71</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The fair value of share-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions:    <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="4" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="4" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.80%-61.65%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62.5% - 65.8%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.00%-65.80%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.23%-1.88%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75% - 1.9%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.74%-2.05%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</td> </tr> </table></div>  </div>

<div>   The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and six months ended June 30, 2016 and 2015 and the year ended December 31, 2015 was:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.96%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research, development and clinical trials</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">839</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,602</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,049</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,529</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,349</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">571</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,639</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">979</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,496</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,279</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,427</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,541</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,397</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,661</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,637</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,632</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,093</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,444</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,860</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following table presents long-lived assets by location:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,959</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,600</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Switzerland</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,385</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,204</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israel</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,862</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,376</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Others</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">457</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">401</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,663</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,581</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,122</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,190</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,135</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,164</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,961</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe, Japan and others</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,797</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,837</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">587</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,126</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,919</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,543</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,972</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,751</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,087</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

119845000

149978000

3192000

3518000

5031000

4618000

12992000

5458000

The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2023. 2023 The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2019. 2019

381000

133000

532000 283000

220316

3.59

220316

975644

888219

18.09

3.59

950637 825240

825240

P4Y

P10Y

12898636

10134829

2127275

78243

11358621

5586108

11157637

8.20

13.86

0.21

17.86

9.77

4.86

9.71

P6Y3M

0.5900

0.6580

0.0174

0.0205

0.00

0.5980

0.625

0.6165

0.658

0.0123

0.0175

0.0188

0.019

170000

6000

311000

19000

174000

839000

628000

1602000

1049000

2529000

1349000

571000

2639000

979000

2496000

3279000

1427000

6541000

2397000

6661000

5637000

2632000

11093000

4444000

11860000

1667785

5959000

6600000

6385000

4204000

1862000

1376000

457000

401000

14663000

12581000

16122000

6190000

28135000

11164000

30961000

1797000

353000

2837000

587000

2126000

P5Y

100000000

25000000

75000000

2016-07

100000000

0.10

0.015

0.0075

0.030

0.020

0.010

2020-01-31

Quarterly

491000

1739000

6412000

1582000 1582000 Net of issuance expenses of $319 Net of issuance expenses (including underwriter fees) of $15,742 EX-101.SCH 9 nvcr-20160630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY(Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100070 - Statement - CONDENSED INTERIM CONSOLIDATED CASH FLOWS link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Organization and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Short-Term Investments link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Commitments and Contingent Liabilities link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Share Capital link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Equity Incentive Plan link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Supplemental Information link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Long-Term Loan, Net of Discount and Issuance Costs link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Impairment of Field Equipment link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Organization and Basis of Presentation (Policies) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Equity Incentive Plan (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Supplemental Information (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Short-Term Investments - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Inventories - Schedule of Inventories (Details) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Commitments and Contingent Liabilities - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Share Capital - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Equity Incentive Plan - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Equity Incentive Plan - Schedule of Stock Option Plan (Details) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Equity Incentive Plan - Schedule of Fair Value of Share Based Awards Using Black-Scholes Option Pricing Model (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Equity Incentive Plan - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Supplemental Information - Schedule of Long-Lived Assets by Location (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Supplemental Information - Schedule of Revenues by Geographic Region (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Long-Term Loan, Net of Discount and Issuance Costs - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Impairment of Field Equipment - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 10 nvcr-20160630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 nvcr-20160630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 nvcr-20160630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document document and entity information. Document Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Receivables and prepaid expenses. Field equipment, net, noncurrent. Severance pay fund noncurrent. Employee related liabilities noncurrent. Statement Of Financial Position [Abstract] ASSETS Assets [Abstract] CURRENT ASSETS: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments Held To Maturity Securities Current Restricted cash Restricted Cash And Cash Equivalents At Carrying Value Receivables and prepaid expenses Receivables And Prepaid Expenses Inventories Inventory Net Total current assets Assets Current LONG-TERM ASSETS: Assets Noncurrent [Abstract] Property and equipment, net Property Plant And Equipment Net Field equipment, net Field Equipment Net Noncurrent Severance pay fund Severance Pay Fund Noncurrent Other long-term assets Other Assets Noncurrent Total long-term assets Assets Noncurrent TOTAL ASSETS Assets LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities And Stockholders Equity [Abstract] CURRENT LIABILITIES: Liabilities Current [Abstract] Trade payables Accounts Payable Trade Current Other payables and accrued expenses Other Accounts Payable And Accrued Liabilities Total current liabilities Liabilities Current LONG-TERM LIABILITIES: Liabilities Noncurrent [Abstract] Long-term loan, net of discount and issuance costs Long Term Debt Noncurrent Employee benefit liabilities Employee Related Liabilities Non Current Other long-term liabilities Other Liabilities Noncurrent Total long-term liabilities Liabilities Noncurrent TOTAL LIABILITIES Liabilities COMMITMENTS AND CONTINGENCIES Commitments And Contingencies SHAREHOLDERS' EQUITY: Stockholders Equity [Abstract] Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 85,774,774 shares and 83,778,581 shares at June 30, 2016 and December 31, 2015, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total shareholders' equity Stockholders Equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities And Stockholders Equity Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Unlimited Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Net revenues Sales Revenue Net Cost of revenues Cost Of Revenue Impairment of field equipment Production Related Impairments Or Charges Gross profit Gross Profit Operating costs and expenses: Operating Expenses [Abstract] Research, development and clinical trials Research And Development Expense Sales and marketing Selling And Marketing Expense General and administrative General And Administrative Expense Total operating costs and expenses Operating Expenses Operating loss Operating Income Loss Financial expenses, net Interest And Debt Expense Loss before income tax expense Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax expense Income Tax Expense Benefit Net loss Net Income Loss Basic and diluted net loss per ordinary share Earnings Per Share Basic And Diluted Weighted average number of ordinary shares used in computing basic and diluted net loss per share Weighted Average Number Of Share Outstanding Basic And Diluted Statement Of Income And Comprehensive Income [Abstract] Net loss Other comprehensive loss, net of tax : Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Change in foreign currency translation adjustments Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Pension benefit plan Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax Total comprehensive loss Comprehensive Income Net Of Tax Stock issued during period value exercise of options and warrants. Stock issued during period shares exercise of options and warrants. Issuances of stock and options shares for settlement net of indemnification. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Ordinary Shares Common Stock [Member] Preferred Shares Preferred Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Income [Member] Accumulated Deficit Retained Earnings [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Outstanding nonredeemable series J preferred stock or outstanding series J preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer. Series J Preferred Stock Series J Preferred Stock [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Over-Allotment Over Allotment Option [Member] Statement [Line Items] Statement [Line Items] Balance Balance (in shares) Shares Outstanding Share-based compensation to employees Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Exercise of options and warrants Stock Issued During Period Value Exercise Of Options And Warrants Exercise of options and warrants (in shares) Stock Issued During Period Shares Exercise Of Options And Warrants Issuance of shares, net Stock Issued During Period Value New Issues Issuance of shares, net (in shares) Stock Issued During Period Shares New Issues Issuance of shares and options in respect of settlement, net of fair value of shares provided as indemnification (in shares) Issuances Of Stock And Options Shares For Settlement Net Of Indemnification Conversion of preferred shares to ordinary shares Stock Issued During Period Shares Conversion Of Convertible Securities Other comprehensive loss, net of tax benefit Other Comprehensive Income Loss Net Of Tax Balance Balance (in shares) Share issuance expenses Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Accrued interest expense. Increase (decrease) in receivables and prepaid expenses. Payments to acquire of field equipment. Cash paid during the period for. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation And Amortization Asset write-downs and impairment of field equipment Asset Impairment Charges Accrued interest expense Accrued Interest Expense Share-based compensation to employees Share Based Compensation Amortization of discount (premium) Amortization Of Debt Discount Premium Increase in receivables and prepaid expenses Increase Decrease In Receivables And Prepaid Expenses Increase in inventories Increase Decrease In Inventories Increase in other long-term assets Increase Decrease In Other Noncurrent Assets Increase in trade payables Increase Decrease In Accounts Payable Trade Increase in other payables and accrued expenses Increase Decrease In Other Accounts Payable And Accrued Liabilities Increase in employee benefit liabilities, net Increase Decrease In Employee Related Liabilities Increase (decrease) in other long-term liabilities Increase Decrease In Other Noncurrent Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash flows from investing activities: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Purchase of property and equipment Payments To Acquire Property Plant And Equipment Purchase of field equipment Payments To Acquire Of Field Equipment Decrease (increase) in restricted cash Increase Decrease In Restricted Cash Proceeds from maturity of short-term investments Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities Purchase of short-term investments Payments To Acquire Held To Maturity Securities Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash flows from financing activities: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Proceeds from issuance of shares, net Proceeds From Issuance Of Common Stock Proceeds from long-term loan, net Proceeds From Issuance Of Long Term Debt Deferred IPO costs Payments Of Stock Issuance Costs Repayment of other long-term loan Repayments Of Other Long Term Debt Purchase of shares in respect of settlement Payments For Repurchase Of Common Stock Exercise of options and warrants Proceeds From Issuance Or Sale Of Equity Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Effect of exchange rate changes on cash and cash equivalents Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations Increase (decrease) in cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period Supplemental cash flow activities: Supplemental Cash Flow Information [Abstract] Cash paid during the period for: Cash Paid During Period For [Abstract] Income taxes Income Taxes Paid Net Interest Interest Paid Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization and Basis of Presentation Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Marketable Securities Current [Abstract] Short-Term Investments Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingent Liabilities Commitments And Contingencies Disclosure [Text Block] Disclosure of share capital. Share Based Compensation Allocation And Classification In Financial Statements [Abstract] Share Capital Disclosure Of Share Capital [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Equity Incentive Plan Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Geographic Areas Long Lived Assets [Abstract] Supplemental Information Segment Reporting Disclosure [Text Block] Debt Disclosure [Abstract] Long-Term Loan, Net of Discount and Issuance Costs Debt Disclosure [Text Block] Impairment Or Disposal Of Tangible Assets Disclosure [Abstract] Impairment of Field Equipment Restructuring Impairment And Other Activities Disclosure [Text Block] Recently Issued Accounting Pronouncement New Accounting Pronouncements Policy Policy [Text Block] Schedule of Inventories Schedule Of Inventory Current Table [Text Block] Schedule of Stock Option Plans Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Schedule of Fair Value of Share Based Awards Using Black-Scholes Option Pricing Model Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Text Block] Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of Long-Lived Assets by Location Long Lived Assets By Geographic Areas Table [Text Block] Schedule of Revenues by Geographic Region Schedule Of Revenues From External Customers And Long Lived Assets By Geographical Areas Table [Text Block] Investments Debt And Equity Securities [Abstract] Estimated fair value of short-term investments Held To Maturity Securities Fair Value Raw materials Inventory Raw Materials Net Of Reserves Work in progress Inventory Work In Process Net Of Reserves Finished products Inventory Finished Goods Net Of Reserves Total Operating lease expiration description. Operating lease agreement expiration period. Loss Contingencies [Table] Loss Contingencies [Table] Range Range [Axis] Range Range [Member] Maximum Maximum [Member] Property, Plant and Equipment, Type Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type Property Plant And Equipment Type [Domain] Motor Vehicles Vehicles [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Operating lease expiration description Operating Lease Expiration Description Operating lease agreements, expiration year Operating Lease Agreement Expiration Period Operating lease commitments. Pledged bank deposits Deposits Assets Operating Lease Commitments Operating Lease Commitments Warrants exercised to ordinary shares. Options issued to purchase ordinary shares. Share capital. Schedule of share capital. Schedule Of Share Capital [Table] Schedule Of Share Capital [Table] Warrants to purchase ordinary share one. Warrants to Purchase 220,316 Ordinary Shares Warrants To Purchase Ordinary Share One [Member] Warrants to purchase ordinary share two. Warrants to Purchase 975,644 Ordinary Shares Warrants To Purchase Ordinary Share Two [Member] Warrants to purchase ordinary share three. Warrants to Purchase 888,219 Ordinary Shares Warrants To Purchase Ordinary Share Three [Member] Warrant Warrant [Member] Share Capital [Line Items] Share Capital [Line Items] Warrants issued to purchase of ordinary shares Debt Conversion Converted Instrument Warrants Or Options Issued1 Warrants exercise price Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Warrants exercised to ordinary shares Warrants Exercised To Ordinary Shares Options issued to purchase ordinary shares Options Issued To Purchase Ordinary Shares Ordinary shares issued upon option exercise Stock Issued During Period Shares Stock Options Exercised Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] EX-101.PRE 13 nvcr-20160630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 14 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Jul. 26, 2016
Document Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2
Trading Symbol	NVCR
Entity Registrant Name	Novocure Ltd
Entity Central Index Key	0001645113
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		85,774,774

XML 15 R2.htm IDEA: XBRL DOCUMENT

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 80,871	$ 119,423
Short-term investments	119,979	150,001
Restricted cash	99	87
Receivables and prepaid expenses	12,534	10,799
Inventories	21,215	13,594
Total current assets	234,698	293,904
LONG-TERM ASSETS:
Property and equipment, net	8,813	6,552
Field equipment, net	5,850	6,029
Severance pay fund	82	79
Other long-term assets	1,076	772
Total long-term assets	15,821	13,432
TOTAL ASSETS	250,519	307,336
CURRENT LIABILITIES:
Trade payables	22,007	16,755
Other payables and accrued expenses	12,611	11,872
Total current liabilities	34,618	28,627
LONG-TERM LIABILITIES:
Long-term loan, net of discount and issuance costs	23,292	23,097
Employee benefit liabilities	2,592	2,057
Other long-term liabilities	3,371	2,735
Total long-term liabilities	29,255	27,889
TOTAL LIABILITIES	63,873	56,516
COMMITMENTS AND CONTINGENCIES	0	0
SHAREHOLDERS' EQUITY:
Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 85,774,774 shares and 83,778,581 shares at June 30, 2016 and December 31, 2015, respectively	0	0
Additional paid-in capital	652,460	640,406
Accumulated other comprehensive loss	(1,684)	(1,505)
Accumulated deficit	(464,130)	(388,081)
Total shareholders' equity	186,646	250,820
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 250,519	$ 307,336

XML 16 R3.htm IDEA: XBRL DOCUMENT

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0	$ 0
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares issued	85,774,774	83,778,581
Common stock, shares outstanding	85,774,774	83,778,581

XML 17 R4.htm IDEA: XBRL DOCUMENT

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Income Statement [Abstract]
Net revenues	$ 17,919	$ 6,543	$ 30,972	$ 11,751	$ 33,087
Cost of revenues	9,797	4,750	17,779	8,647	20,610
Impairment of field equipment	6,412		6,412
Gross profit	1,710	1,793	6,781	3,104	12,477
Operating costs and expenses:
Research, development and clinical trials	11,318	12,765	22,763	22,692	43,748
Sales and marketing	14,598	8,866	27,906	15,221	38,861
General and administrative	13,031	7,368	25,287	14,343	33,864
Total operating costs and expenses	38,947	28,999	75,956	52,256	116,473
Operating loss	(37,237)	(27,206)	(69,175)	(49,152)	(103,996)
Financial expenses, net	555	876	1,104	1,467	3,151
Loss before income tax expense	(37,792)	(28,082)	(70,279)	(50,619)	(107,147)
Income tax expense	2,820	1,275	5,770	2,011	4,434
Net loss	$ (40,612)	$ (29,357)	$ (76,049)	$ (52,630)	$ (111,581)
Basic and diluted net loss per ordinary share	$ (0.48)	$ (2.36)	$ (0.90)	$ (4.12)	$ (3.67)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	85,274,683	12,427,442	84,843,028	12,783,881	30,401,603

XML 18 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (40,612)	$ (29,357)	$ (76,049)	$ (52,630)	$ (111,581)
Other comprehensive loss, net of tax :
Change in foreign currency translation adjustments	56		56
Pension benefit plan	235		(235)		(1,505)
Total comprehensive loss	$ (40,321)	$ (29,357)	$ (76,228)	$ (52,630)	$ (113,086)

XML 19 R6.htm IDEA: XBRL DOCUMENT

CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands

Total

Over-Allotment

^[1]

Series J Preferred Stock

^[2]

Ordinary Shares

Over-Allotment

Preferred Shares

Series J Preferred Stock

Additional Paid-in Capital

Over-Allotment

^[1]

Additional Paid-in Capital

Series J Preferred Stock

^[2]

Accumulated Other Comprehensive Loss

Accumulated Deficit

Balance at Dec. 31, 2014

$ 97,875

$ 374,375

$ (276,500)

Balance (in shares) at Dec. 31, 2014

13,431,414

58,676,017

Share-based compensation to employees

11,860

Exercise of options and warrants

2,038

Exercise of options and warrants (in shares)

731,665

Issuance of shares, net

$ 157,534

$ 94,599

$ 157,534

$ 94,599

Issuance of shares, net (in shares)

7,876,195

4,068,500

Issuance of shares and options in respect of settlement, net of fair value of shares provided as indemnification (in shares)

(1,005,210)

Conversion of preferred shares to ordinary shares

62,744,517

(62,744,517)

Other comprehensive loss, net of tax benefit

(1,505)

$ (1,505)

Net loss

(111,581)

Balance at Dec. 31, 2015

250,820

640,406

(1,505)

(388,081)

Balance (in shares) at Dec. 31, 2015

83,778,581

Share-based compensation to employees

11,093

Exercise of options and warrants

961

Exercise of options and warrants (in shares)

1,996,193

Other comprehensive loss, net of tax benefit

(179)

Net loss

(76,049)

Balance at Jun. 30, 2016

$ 186,646

$ 652,460

$ (1,684)

$ (464,130)

Balance (in shares) at Jun. 30, 2016

85,774,774

[1]	Net of issuance expenses (including underwriter fees) of $15,742
[2]	Net of issuance expenses of $319

XML 20 R7.htm IDEA: XBRL DOCUMENT

CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY(Parenthetical) $ in Thousands	6 Months Ended
	Jun. 30, 2016 USD ($)
Series J Preferred Stock
Share issuance expenses	$ 319
Over-Allotment
Share issuance expenses	$ 15,742

XML 21 R8.htm IDEA: XBRL DOCUMENT

CONDENSED INTERIM CONSOLIDATED CASH FLOWS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (40,612)	$ (29,357)	$ (76,049)	$ (52,630)	$ (111,581)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,407	588	2,510	1,112	3,153
Asset write-downs and impairment of field equipment	6,425	11	6,430	42	46
Accrued interest expense	(637)	307		719	672
Share-based compensation to employees	5,637	2,632	11,093	4,444	11,860
Amortization of discount (premium)	(39)	88	(56)	143	329
Increase in receivables and prepaid expenses	(1,672)	(2,079)	(2,208)	(3,026)	(5,088)
Increase in inventories	(4,769)	(1,415)	(7,621)	(5,147)	(10,148)
Increase in other long-term assets	(111)	(161)	(278)	(171)	(381)
Increase in trade payables	2,321	3,757	4,144	3,085	6,961
Increase in other payables and accrued expenses	2,399	3,237	756	518	3,579
Increase in employee benefit liabilities, net	32		270	7	133
Increase (decrease) in other long-term liabilities	225	(799)	638	(753)	581
Net cash used in operating activities	(29,394)	(23,191)	(60,371)	(51,657)	(99,884)
Cash flows from investing activities:
Purchase of property and equipment	(2,338)	(1,808)	(3,340)	(2,417)	(4,667)
Purchase of field equipment	(4,274)	(1,142)	(6,100)	(2,180)	(5,604)
Decrease (increase) in restricted cash	(13)	40	(12)	(33)	(26)
Proceeds from maturity of short-term investments		2,000	150,000	47,000	104,000
Purchase of short-term investments		(36,995)	(119,728)	(58,992)	(208,998)
Net cash provided by (used in) investing activities	(6,625)	(37,905)	20,820	(16,622)	(115,295)
Cash flows from financing activities:
Proceeds from issuance of shares, net		94,599		94,599	252,133
Proceeds from long-term loan, net	17	(920)	17	22,886	22,886
Deferred IPO costs		(294)		(294)
Repayment of other long-term loan	(19)	(15)	(35)	(31)	(63)
Purchase of shares in respect of settlement				(5)	(5)
Exercise of options and warrants	904	16	961	19	2,038
Net cash provided by financing activities	902	93,386	943	117,174	276,989
Effect of exchange rate changes on cash and cash equivalents	56		56
Increase (decrease) in cash and cash equivalents	(35,061)	32,290	(38,552)	48,895	61,810
Cash and cash equivalents at the beginning of the period	115,932	74,218	119,423	57,613	57,613
Cash and cash equivalents at the end of the period	80,871	106,508	80,871	106,508	119,423
Cash paid during the period for:
Income taxes	1,587	171	3,169	266	1,489
Interest	$ 1,269	$ 422	$ 1,933	$ 428	$ 1,688

XML 22 R9.htm IDEA: XBRL DOCUMENT

Organization and Basis of Presentation	6 Months Ended
Organization and Basis of Presentation	Jun. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Basis of Presentation	NOTE 1: ORGANIZATION AND BASIS OF PRESENTATION Organization. NovoCure Limited (including its consolidated subsidiaries, the “Company”) was incorporated in Jersey and is principally engaged in the development, manufacture and commercialization of TTFields for the treatment of solid tumors. Since inception, the Company has devoted substantially all of its efforts to developing and commercializing a family of products to deliver TTFields for a variety of solid tumor indications, raising capital and recruiting personnel. The Company has regulatory approvals and clearances in certain countries for Optune, its first TTFields delivery system, to treat glioblastoma (“GBM”). The Company commenced marketing Optune in the United States at the end of 2011, in certain countries in Europe in 2014 and in Japan in 2015. Financial statement preparation. The accompanying condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries, and intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the “2015 10-K”) filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2016. The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the 2015 10-K are applied consistently in these unaudited interim consolidated financial statements. Recently Issued Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In April 2016, FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASU 2016-10 covers two specific topics: performance obligations and licensing. This amendment includes guidance on immaterial promised goods or services, shipping or handling activities, separately identifiable performance obligations, functional or symbolic intellectual property licenses, sales-based and usage-based royalties, license restrictions (time, use, geographical) and licensing renewals. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In May 2016, FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

XML 23 R10.htm IDEA: XBRL DOCUMENT

Short-Term Investments	6 Months Ended
Short-Term Investments	Jun. 30, 2016
Marketable Securities Current [Abstract]
Short-Term Investments	NOTE 2: SHORT-TERM INVESTMENTS The Company invests in marketable U.S. Treasury Bills (“T-bills”) that are classified as held-to-maturity securities. The amortized cost and recorded basis of the T-bills are presented as short-term investments in the amount of $119,979 and $150,001 as of June 30, 2016 and December 31, 2015, respectively, and their estimated fair value as of June 30, 2016 and December 31, 2015 was $119,845 and $149,978, respectively.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

XML 24 R11.htm IDEA: XBRL DOCUMENT

Inventories

6 Months Ended

Jun. 30, 2016

Inventory Disclosure [Abstract]

Inventories

NOTE 3: INVENTORIES

	June 30,		December 31,
	2016		2015
	Unaudited		Audited
Raw materials	$	3,192	$	3,518
Work in progress		5,031		4,618
Finished products		12,992		5,458
Total	$	21,215	$	13,594

XML 25 R12.htm IDEA: XBRL DOCUMENT

Commitments and Contingent Liabilities	6 Months Ended
Commitments and Contingent Liabilities	Jun. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	NOTE 4: COMMITMENTS AND CONTINGENT LIABILITIES The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2023. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2019. As of June 30, 2016 and December 31, 2015, the Company pledged bank deposits of $381 and $133, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained guarantees by the bank for the fulfillment of the Company’s lease commitments of $532 and $283, respectively.

XML 26 R13.htm IDEA: XBRL DOCUMENT

Share Capital	6 Months Ended
Share Capital	Jun. 30, 2016
Share Based Compensation Allocation And Classification In Financial Statements [Abstract]
Share Capital	NOTE 5: SHARE CAPITAL For the six months ended June 30, 2016, warrants to purchase 220,316 ordinary shares with an exercise price of $3.59 were exercised, resulting in the issuance of 220,316 ordinary shares, and warrants to purchase 975,644and 888,219 ordinary shares with exercise prices of $18.09 and $3.59 per share, respectively, were cashlessly exercised, resulting in the issuance of 950,637 ordinary shares. For the six months ended June 30, 2016, options to purchase 825,240 ordinary shares were exercised, resulting in the issuance of 825,240 ordinary shares. For additional information on option exercises, please see Note 6.

XML 27 R14.htm IDEA: XBRL DOCUMENT

Equity Incentive Plan

6 Months Ended

Jun. 30, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity Incentive Plan

NOTE 6: EQUITY INCENTIVE PLAN

As of June 30, 2016, 12,898,636 ordinary shares were available for grant under the 2015 Plan.

A summary of the status of the Company’s option plans as of June 30, 2016 and changes during the period then ended is presented below:

	Six months ended June 30, 2016
	Unaudited
	Number of options			Weighted average exercise price
Outstanding at beginning of year		10,134,829		$	8.20
Granted		2,127,275			13.86
Exercised		(825,240	)		0.21
Forfeited and cancelled		(78,243	)		17.86

Outstanding as of June 30, 2016		11,358,621			9.77

Exercisable options		5,586,108			4.86

Vested and expected to vest		11,157,637		$	9.71

The fair value of share-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions:

	Six months ended June 30,			Year ended December 31,
	2016	2015		2015
	Unaudited			Audited
Expected term (years)	6.25		6.25	6.25
Expected volatility	59.80%-61.65%	62.5% - 65.8%		59.00%-65.80%
Risk-free interest rate	1.23%-1.88%	1.75% - 1.9%		1.74%-2.05%
Dividend yield	0%	0%		0%

	Three months ended June 30,				Six months ended June 30,				Year ended December 31,
	2016		2015		2016		2015		2015
	Unaudited				Unaudited				Audited
Cost of revenues	$	170	$	6	$	311	$	19	$	174
Research, development and clinical trials		839		628		1,602		1,049		2,529
Sales and marketing		1,349		571		2,639		979		2,496
General and administrative		3,279		1,427		6,541		2,397		6,661
Total share-based compensation expense	$	5,637	$	2,632	$	11,093	$	4,444	$	11,860

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 28 R15.htm IDEA: XBRL DOCUMENT

Supplemental Information

6 Months Ended

Jun. 30, 2016

Geographic Areas Long Lived Assets [Abstract]

Supplemental Information

NOTE 7: SUPPLEMENTAL INFORMATION

The Company operates in a single reportable segment.

The following table presents long-lived assets by location:

	June 30,		December 31,
	2016		2015
	Unaudited		Audited
United States	$	5,959	$	6,600
Switzerland		6,385		4,204
Israel		1,862		1,376
Others		457		401
Total	$	14,663	$	12,581

The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:

	Three months ended June 30,				Six months ended June 30,				Year ended December 31,
	2016		2015		2016		2015		2015
	Unaudited				Unaudited				Audited
United States	$	16,122	$	6,190	$	28,135	$	11,164	$	30,961
Europe, Japan and others		1,797		353		2,837		587		2,126
Total	$	17,919	$	6,543	$	30,972	$	11,751	$	33,087

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

XML 29 R16.htm IDEA: XBRL DOCUMENT

Long-Term Loan, Net of Discount and Issuance Costs	6 Months Ended
Long-Term Loan, Net of Discount and Issuance Costs	Jun. 30, 2016
Debt Disclosure [Abstract]
Long-Term Loan, Net of Discount and Issuance Costs	NOTE 8: LONG-TERM LOAN, NET OF DISCOUNT AND ISSUANCE COSTS In January 2015, the Company entered into a five-year term loan agreement and related documents (the “Term Loan Credit Facility”) with a lender to draw up to $100,000. In January 2015, the Company drew $25,000 from the lender. The Company had the option to draw the remaining $75,000 at its option at any time through June 30, 2016. On June 30, 2016, the Company provided to the lender a drawdown notice for the remaining $75,000, and it received funds in July 2016. Following the July 2016 closing, our material outstanding indebtedness under the Term Loan Credit Facility is $100 million. Interest on the outstanding loan is 10% annually, payable quarterly in arrears. In addition, there is a 1.5% funding fee payable on the amount drawn on the funding date, a 0.75% pay-down fee on all principal amount repayments to be paid on the date such payments of principal are made and a pre-payment fee of 3.0%, 2.0% or 1.0% if the Company prepays outstanding loan amounts prior to the first, second or third year, respectively, from the initial funding date. The entire outstanding principal loan is due on January 2020. The loan is secured by a first priority security interest in substantially all assets of the Company. The Term Loan Credit Facility sets forth certain affirmative and negative covenants with which the Company must comply on a quarterly basis through the term of the loan. As of June 30, 2016, the Company was in compliance with such covenants. The total discount of $491 and additional issuance costs of $1,739 are presented net of the loan and are amortized to interest expense over the five year term of the loan using the effective interest method.

XML 30 R17.htm IDEA: XBRL DOCUMENT

Impairment of Field Equipment	6 Months Ended
Impairment of Field Equipment	Jun. 30, 2016
Impairment Or Disposal Of Tangible Assets Disclosure [Abstract]
Impairment of Field Equipment	NOTE 9: IMPAIRMENT OF FIELD EQUIPMENT The Company received U.S. Food and Drug Administration approval on its premarket approval supplement application to market its second generation Optune System in the United States on July 13, 2016. The Company has begun converting patients in the United States from the first generation Optune System to the second generation Optune System and expects to complete the conversion over the next few months. Manufacturing of the first generation Optune System has been terminated. For the three and six months ended June 30, 2016, the Company recorded an impairment loss with respect to the write-off of first generation Optune System field equipment (finished goods and production stage) in the amount of $6,412, including advances for materials purchased and liabilities incurred to vendors of $1,582 that are not recoverable, presented in cost of revenues. The Company does not expect the conversion to result in an additional material impairment charge in the future.

XML 31 R18.htm IDEA: XBRL DOCUMENT

Organization and Basis of Presentation (Policies)	6 Months Ended
Organization and Basis of Presentation (Policies)	Jun. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Recently Issued Accounting Pronouncement	Recently Issued Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In April 2016, FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASU 2016-10 covers two specific topics: performance obligations and licensing. This amendment includes guidance on immaterial promised goods or services, shipping or handling activities, separately identifiable performance obligations, functional or symbolic intellectual property licenses, sales-based and usage-based royalties, license restrictions (time, use, geographical) and licensing renewals. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In May 2016, FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

XML 32 R19.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

6 Months Ended

Jun. 30, 2016

Inventory Disclosure [Abstract]

Schedule of Inventories

	June 30,		December 31,
	2016		2015
	Unaudited		Audited
Raw materials	$	3,192	$	3,518
Work in progress		5,031		4,618
Finished products		12,992		5,458
Total	$	21,215	$	13,594

XML 33 R20.htm IDEA: XBRL DOCUMENT

Equity Incentive Plan (Tables)

6 Months Ended

Jun. 30, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Stock Option Plans

A summary of the status of the Company’s option plans as of June 30, 2016 and changes during the period then ended is presented below:

	Six months ended June 30, 2016
	Unaudited
	Number of options			Weighted average exercise price
Outstanding at beginning of year		10,134,829		$	8.20
Granted		2,127,275			13.86
Exercised		(825,240	)		0.21
Forfeited and cancelled		(78,243	)		17.86

Outstanding as of June 30, 2016		11,358,621			9.77

Exercisable options		5,586,108			4.86

Vested and expected to vest		11,157,637		$	9.71

Schedule of Fair Value of Share Based Awards Using Black-Scholes Option Pricing Model

The fair value of share-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions:

	Six months ended June 30,			Year ended December 31,
	2016	2015		2015
	Unaudited			Audited
Expected term (years)	6.25		6.25	6.25
Expected volatility	59.80%-61.65%	62.5% - 65.8%		59.00%-65.80%
Risk-free interest rate	1.23%-1.88%	1.75% - 1.9%		1.74%-2.05%
Dividend yield	0%	0%		0%

Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards

	Three months ended June 30,				Six months ended June 30,				Year ended December 31,
	2016		2015		2016		2015		2015
	Unaudited				Unaudited				Audited
Cost of revenues	$	170	$	6	$	311	$	19	$	174
Research, development and clinical trials		839		628		1,602		1,049		2,529
Sales and marketing		1,349		571		2,639		979		2,496
General and administrative		3,279		1,427		6,541		2,397		6,661
Total share-based compensation expense	$	5,637	$	2,632	$	11,093	$	4,444	$	11,860

XML 34 R21.htm IDEA: XBRL DOCUMENT

Supplemental Information (Tables)

6 Months Ended

Jun. 30, 2016

Geographic Areas Long Lived Assets [Abstract]

Schedule of Long-Lived Assets by Location

The following table presents long-lived assets by location:

	June 30,		December 31,
	2016		2015
	Unaudited		Audited
United States	$	5,959	$	6,600
Switzerland		6,385		4,204
Israel		1,862		1,376
Others		457		401
Total	$	14,663	$	12,581

Schedule of Revenues by Geographic Region

The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:

	Three months ended June 30,				Six months ended June 30,				Year ended December 31,
	2016		2015		2016		2015		2015
	Unaudited				Unaudited				Audited
United States	$	16,122	$	6,190	$	28,135	$	11,164	$	30,961
Europe, Japan and others		1,797		353		2,837		587		2,126
Total	$	17,919	$	6,543	$	30,972	$	11,751	$	33,087

XML 35 R22.htm IDEA: XBRL DOCUMENT

Short-Term Investments - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Investments Debt And Equity Securities [Abstract]
Short-term investments	$ 119,979	$ 150,001
Estimated fair value of short-term investments	$ 119,845	$ 149,978

XML 36 R23.htm IDEA: XBRL DOCUMENT

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 3,192	$ 3,518
Work in progress	5,031	4,618
Finished products	12,992	5,458
Total	$ 21,215	$ 13,594

XML 37 R24.htm IDEA: XBRL DOCUMENT

Commitments and Contingent Liabilities - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Loss Contingencies [Line Items]
Operating lease expiration description	The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2023.
Pledged bank deposits	$ 381	$ 133
Operating Lease Commitments	$ 532	$ 283
Motor Vehicles
Loss Contingencies [Line Items]
Operating lease expiration description	The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2019.
Maximum
Loss Contingencies [Line Items]
Operating lease agreements, expiration year	2023
Maximum \| Motor Vehicles
Loss Contingencies [Line Items]
Operating lease agreements, expiration year	2019

XML 38 R25.htm IDEA: XBRL DOCUMENT

Share Capital - Additional Information (Details)	6 Months Ended
Share Capital - Additional Information (Details)	Jun. 30, 2016 $ / shares shares
Share Capital [Line Items]
Options issued to purchase ordinary shares	825,240
Ordinary shares issued upon option exercise	825,240
Warrants to Purchase 220,316 Ordinary Shares
Share Capital [Line Items]
Warrants issued to purchase of ordinary shares	220,316
Warrants exercise price \| $ / shares	$ 3.59
Warrants exercised to ordinary shares	220,316
Warrants to Purchase 975,644 Ordinary Shares
Share Capital [Line Items]
Warrants issued to purchase of ordinary shares	975,644
Warrants exercise price \| $ / shares	$ 18.09
Warrants to Purchase 888,219 Ordinary Shares
Share Capital [Line Items]
Warrants issued to purchase of ordinary shares	888,219
Warrants exercise price \| $ / shares	$ 3.59
Warrant
Share Capital [Line Items]
Warrants exercised to ordinary shares	950,637

XML 39 R26.htm IDEA: XBRL DOCUMENT

Equity Incentive Plan - Additional Information (Details)	6 Months Ended
	Jun. 30, 2016 shares
ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Ordinary shares available for grants	1,667,785
Shares offered under plan	0
2015 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option granted vesting period	4 years
Option granted expiration period	10 years
Ordinary shares available for grants	12,898,636

XML 40 R27.htm IDEA: XBRL DOCUMENT

Equity Incentive Plan - Schedule of Stock Option Plan (Details)	6 Months Ended
	Jun. 30, 2016 $ / shares shares
Number of options
Number of options, Outstanding at beginning of year \| shares	10,134,829
Number of options, Granted \| shares	2,127,275
Number of options, Exercised \| shares	(825,240)
Number of options, Forfeited and cancelled \| shares	(78,243)
Number of options, Outstanding at ending of year \| shares	11,358,621
Number of options, Exercisable options \| shares	5,586,108
Number of options, Vested and expected to vest \| shares	11,157,637
Weighted average exercise price
Weighted average exercise price, Outstanding at beginning of year \| $ / shares	$ 8.20
Weighted average exercise price, Granted \| $ / shares	13.86
Weighted average exercise price, Exercised \| $ / shares	0.21
Weighted average exercise price, Forfeited and cancelled \| $ / shares	17.86
Weighted average exercise price, Outstanding at end of year \| $ / shares	9.77
Weighted average exercise price, Exercisable options \| $ / shares	4.86
Weighted average exercise price, Vested and expected to vest \| $ / shares	$ 9.71

XML 41 R28.htm IDEA: XBRL DOCUMENT

Equity Incentive Plan - Schedule of Fair Value of Share Based Awards Using Black-Scholes Option Pricing Model (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Expected term (years)	6 years 3 months	6 years 3 months	6 years 3 months
Expected volatility, minimum	59.80%	62.50%	59.00%
Expected volatility, maximum	61.65%	65.80%	65.80%
Risk-free interest rate, minimum	1.23%	1.75%	1.74%
Risk-free interest rate, maximum	1.88%	1.90%	2.05%
Dividend yield	0.00%	0.00%	0.00%

XML 42 R29.htm IDEA: XBRL DOCUMENT

Equity Incentive Plan - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 5,637	$ 2,632	$ 11,093	$ 4,444	$ 11,860
Cost of Revenues
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	170	6	311	19	174
Research, Development and Clinical Trials
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	839	628	1,602	1,049	2,529
Sales and Marketing
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	1,349	571	2,639	979	2,496
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 3,279	$ 1,427	$ 6,541	$ 2,397	$ 6,661

XML 43 R30.htm IDEA: XBRL DOCUMENT

Supplemental Information - Schedule of Long-Lived Assets by Location (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	$ 14,663	$ 12,581
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	5,959	6,600
Switzerland
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	6,385	4,204
Israel
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	1,862	1,376
Others
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	$ 457	$ 401

XML 44 R31.htm IDEA: XBRL DOCUMENT

Supplemental Information - Schedule of Revenues by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	$ 17,919	$ 6,543	$ 30,972	$ 11,751	$ 33,087
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	16,122	6,190	28,135	11,164	30,961
Europe, Japan and others
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	$ 1,797	$ 353	$ 2,837	$ 587	$ 2,126

XML 45 R32.htm IDEA: XBRL DOCUMENT

Long-Term Loan, Net of Discount and Issuance Costs - Additional Information (Details) - Term Loan - USD ($)	1 Months Ended	6 Months Ended
	Jan. 31, 2015	Jun. 30, 2016
Line Of Credit Facility [Line Items]
Term loan agreement, maturity period	5 years
Line of credit facility, maximum borrowing capacity	$ 100,000,000
Line of credit facility, current borrowing capacity	$ 25,000,000
Line of credit facility, remaining borrowing capacity		$ 75,000,000
Line of credit facility, drawdown received date		2016-07
Term loan credit facility, outstanding		$ 100,000,000
Interest on the outstanding loan		10.00%
Funding fees payable		1.50%
Prepayment fee percent		0.75%
Due date of outstanding principal loan		Jan. 31, 2020
Frequency of payments		Quarterly
Other Long-term Assets
Line Of Credit Facility [Line Items]
Total discount		$ 491,000
Additional deferred issuance costs		$ 1,739,000
First Year
Line Of Credit Facility [Line Items]
Prepayment fee percent		3.00%
Second Year
Line Of Credit Facility [Line Items]
Prepayment fee percent		2.00%
Third Year
Line Of Credit Facility [Line Items]
Prepayment fee percent		1.00%

XML 46 R33.htm IDEA: XBRL DOCUMENT

Impairment of Field Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016
Impaired Long Lived Assets Held And Used [Line Items]
Impairment of field equipment	$ 6,412	$ 6,412
First Generation Optune System Field Equipment \| Cost of Revenues
Impaired Long Lived Assets Held And Used [Line Items]
Impairment of field equipment	6,412	6,412
Advances for materials purchased and liabilities incurred to vendors	$ 1,582	$ 1,582

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 103 166 1 true 30 0 false 4 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.novocure.com/20160630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS Sheet http://www.novocure.com/20160630/taxonomy/role/StatementCONDENSEDINTERIMCONSOLIDATEDBALANCESHEETS CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 100020 - Statement - CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.novocure.com/20160630/taxonomy/role/StatementCONDENSEDINTERIMCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.novocure.com/20160630/taxonomy/role/StatementCONDENSEDINTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 100040 - Statement - CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.novocure.com/20160630/taxonomy/role/StatementCONSOLIDATEDINTERIMSTATEMENTSOFCOMPREHENSIVEINCOME CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME Statements 5 false false R6.htm 100050 - Statement - CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Sheet http://www.novocure.com/20160630/taxonomy/role/StatementCONDENSEDINTERIMSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 100060 - Statement - CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY(Parenthetical) Sheet http://www.novocure.com/20160630/taxonomy/role/StatementCONDENSEDINTERIMSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYParenthetical CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY(Parenthetical) Statements 7 false false R8.htm 100070 - Statement - CONDENSED INTERIM CONSOLIDATED CASH FLOWS Sheet http://www.novocure.com/20160630/taxonomy/role/StatementCONDENSEDINTERIMCONSOLIDATEDCASHFLOWS CONDENSED INTERIM CONSOLIDATED CASH FLOWS Statements 8 false false R9.htm 100080 - Disclosure - Organization and Basis of Presentation Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation Organization and Basis of Presentation Notes 9 false false R10.htm 100090 - Disclosure - Short-Term Investments Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureShortTermInvestments Short-Term Investments Notes 10 false false R11.htm 100100 - Disclosure - Inventories Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureInventories Inventories Notes 11 false false R12.htm 100110 - Disclosure - Commitments and Contingent Liabilities Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureCommitmentsAndContingentLiabilities Commitments and Contingent Liabilities Notes 12 false false R13.htm 100120 - Disclosure - Share Capital Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureShareCapital Share Capital Notes 13 false false R14.htm 100130 - Disclosure - Equity Incentive Plan Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureEquityIncentivePlan Equity Incentive Plan Notes 14 false false R15.htm 100140 - Disclosure - Supplemental Information Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureSupplementalInformation Supplemental Information Notes 15 false false R16.htm 100150 - Disclosure - Long-Term Loan, Net of Discount and Issuance Costs Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureLongTermLoanNetOfDiscountAndIssuanceCosts Long-Term Loan, Net of Discount and Issuance Costs Notes 16 false false R17.htm 100160 - Disclosure - Impairment of Field Equipment Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureImpairmentOfFieldEquipment Impairment of Field Equipment Notes 17 false false R18.htm 100170 - Disclosure - Organization and Basis of Presentation (Policies) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationPolicies Organization and Basis of Presentation (Policies) Policies 18 false false R19.htm 100180 - Disclosure - Inventories (Tables) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureInventoriesTables Inventories (Tables) Tables http://www.novocure.com/20160630/taxonomy/role/DisclosureInventories 19 false false R20.htm 100190 - Disclosure - Equity Incentive Plan (Tables) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureEquityIncentivePlanTables Equity Incentive Plan (Tables) Tables http://www.novocure.com/20160630/taxonomy/role/DisclosureEquityIncentivePlan 20 false false R21.htm 100200 - Disclosure - Supplemental Information (Tables) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureSupplementalInformationTables Supplemental Information (Tables) Tables http://www.novocure.com/20160630/taxonomy/role/DisclosureSupplementalInformation 21 false false R22.htm 100210 - Disclosure - Short-Term Investments - Additional Information (Details) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails Short-Term Investments - Additional Information (Details) Details 22 false false R23.htm 100220 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails Inventories - Schedule of Inventories (Details) Details 23 false false R24.htm 100230 - Disclosure - Commitments and Contingent Liabilities - Additional Information (Details) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalInformationDetails Commitments and Contingent Liabilities - Additional Information (Details) Details 24 false false R25.htm 100240 - Disclosure - Share Capital - Additional Information (Details) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureShareCapitalAdditionalInformationDetails Share Capital - Additional Information (Details) Details 25 false false R26.htm 100250 - Disclosure - Equity Incentive Plan - Additional Information (Details) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails Equity Incentive Plan - Additional Information (Details) Details 26 false false R27.htm 100260 - Disclosure - Equity Incentive Plan - Schedule of Stock Option Plan (Details) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionPlanDetails Equity Incentive Plan - Schedule of Stock Option Plan (Details) Details 27 false false R28.htm 100270 - Disclosure - Equity Incentive Plan - Schedule of Fair Value of Share Based Awards Using Black-Scholes Option Pricing Model (Details) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfFairValueOfShareBasedAwardsUsingBlackScholesOptionPricingModelDetails Equity Incentive Plan - Schedule of Fair Value of Share Based Awards Using Black-Scholes Option Pricing Model (Details) Details 28 false false R29.htm 100280 - Disclosure - Equity Incentive Plan - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfNonCashShareBasedCompensationExpensesRelatedToCompanySEquityBasedAwardsDetails Equity Incentive Plan - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) Details 29 false false R30.htm 100290 - Disclosure - Supplemental Information - Schedule of Long-Lived Assets by Location (Details) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureSupplementalInformationScheduleOfLongLivedAssetsByLocationDetails Supplemental Information - Schedule of Long-Lived Assets by Location (Details) Details 30 false false R31.htm 100300 - Disclosure - Supplemental Information - Schedule of Revenues by Geographic Region (Details) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureSupplementalInformationScheduleOfRevenuesByGeographicRegionDetails Supplemental Information - Schedule of Revenues by Geographic Region (Details) Details 31 false false R32.htm 100310 - Disclosure - Long-Term Loan, Net of Discount and Issuance Costs - Additional Information (Details) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureLongTermLoanNetOfDiscountAndIssuanceCostsAdditionalInformationDetails Long-Term Loan, Net of Discount and Issuance Costs - Additional Information (Details) Details 32 false false R33.htm 100320 - Disclosure - Impairment of Field Equipment - Additional Information (Details) Sheet http://www.novocure.com/20160630/taxonomy/role/DisclosureImpairmentOfFieldEquipmentAdditionalInformationDetails Impairment of Field Equipment - Additional Information (Details) Details 33 false false All Reports Book All Reports nvcr-20160630.xml nvcr-20160630.xsd nvcr-20160630_cal.xml nvcr-20160630_def.xml nvcr-20160630_lab.xml nvcr-20160630_pre.xml true true ZIP 53 0001564590-16-021602-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-16-021602-xbrl.zip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